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The Genetic epidemiology of  Alzheimer’s disease
Alzheimer’s disease (AD) is the most common form of  dementia, account-
ing for 50–60% of  all cases. The prevalence of  dementia is below 1% in per-
sons aged 60–64 years, but shows an almost exponential increase with age, such 
that in people aged 85 years or older the prevalence is between 24% and 33% in 
the western world [1]. Besides age, epidemiological studies have suggested sev-
eral potential risk factors for the disease. Some are related with a decreased re-
serve capacity of  the brain including education [2, 3], others with head injury 
and repair [4], or vascular pathology including, hypertension, coronary heart dis-
ease, atherosclerosis, smoking, hypercholesterolemia, obesity and diabetes [2].
AD is a slowly progressive disorder with insidious onset and progressive impair-
ment of  episodic memory. Key signs include aphasia, apraxia, and agnosia, together 
with general cognitive symptoms, such as impaired judgment, decision-making, and 
orientation [5]. The brain of  an AD patient is characterized by the accumulation 
of  the amyloid ß (Aß) peptide into extracellular plaques and by the formation of  
tangles inside the neurons as a result of  abnormal phosphorylation of  the micro-
tubule-associated protein tau (MAPT). Besides Aß deposits and tangles, a marked 
loss of  neurons in the neocortex and hippocampus is part of  the neurodegenera-
tive process. This process is estimated to start 20 to 30 years before clinical onset 
of  the disease [6]. Over the years, plaque and tangle load increase and at a cer-
tain threshold the first symptoms appear. The pathological changes of  AD are not 
unique but overlaps partly with that of  other degenerative disorders, in particular 
Parkinson’s disease. Parkinson’s disease is the second common neurodegenerative 
disorder in the elderly. Parkinson patients often develop dementia while Alzheimer 
patients may show Lewy body pathology that characterizes Parkinson’s disease. Also, 
both disorders are characterized by disturbances in the ubiquitination machinery [7].
A large proportion of  AD patients can be explained by genetic factors [8]. The 
genes determining risk for AD include (rare) mutations in genes with large ef-
fects on the disease risk and one but most likely several common variants in genes 
with small effects on the risk of  AD. The latter variants may show interaction with 
other genes and environmental risk factors. Variations in four genes have been 
directly linked to the pathogenesis of  AD. Mutations in the amyloid precursor 
protein (APP), Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2) have a major ef-
fect on Aß aggregation, one of  the key pathways involved in Alzheimer disease 
[9] and a common polymorphism (e4) in the gene encoding apolipoprotein E 
(APOE) increases susceptibility to both early and late onset forms of  AD [10, 11].
These four genes together explain less than a quarter of  the disease prevalence, 
4indicating additional genetic risk factors remain to be identified [12, 13]. In addition 
to APOE, more than three dozens of  candidate genes were reported to be associ-
ated with AD. None of  these, however, has been consistently replicated [14, 15]. 
Furthermore, genome screens targeting AD loci were conducted. As reviewed by 
the AlzGene database (www.alzforum.org), the replicated regions from previous ge-
nome screens include: 1p36, 1q21-31, 2p23-24, 4q35, 5p13-15, 6p21, 6q15-16, 6q25-
27, 9p21-22, 10q21-22, 10q25, 12p11-12, 19q13, 21q21-22, and Xp11-21 [16-31].
In this thesis we investigated the genetic susceptibility to AD employing several strat-
egies to find genes involved in the disease. In chapter two, genomic studies aiming 
to find genes involved in AD are presented which rely on genome wide analyses and 
high-throughput genotyping of  chromosomal regions. Chapters 2.1 and 2.2 were per-
formed within the Genetic research in Isolated Populations (GRIP) program, which 
is based in the southwestern part of  the Netherlands. The AD GRIP study is a family 
based study that aims to identify genes involved in complex diseases by selecting af-
fected individuals and their relatives [32]. Chapter 2.1 describes a genome-screen in a 
large serie of  AD patients. Chapter 2.2 describes a detailed study of  the chromosome 
17 region including the microtubule associated tau protein (MAPT) and granulin 
(GRN) genes in patients with AD. Chapter 2.3 describes a study in an extended family 
affected with autosomal dominant AD originating from the east of  The Netherlands.
We also performed four candidate gene studies, which are presented in chapter 3. 
These studies were carried out in the Rotterdam Study and the AD GRIP study. The 
Rotterdam study is a population-based follow-up study of  7983 persons age 55 years 
and over who have been followed now for 12 years [33]. The first two chapters (3.1 
and 3.2) focus on AD. In chapters 3.3 and 3.4, we are linking our studies of  AD to 
the genetics of  Parkinson’s disease. Chapter 3.1 describes the association of  the cy-
clin-dependant kinase 5 (CDK5) gene and AD. In chapter 3.2 we describe the asso-
ciation between the cholesteryl ester transfer protein (CETP) and AD. In chapter 3.3 
we assessed the relationship of  the ubiquilin 1 (UBQLN1) gene and AD, Parkinson’s 
disease and cognitive function. In chapter 3.4 we evaluated the effect of  a deletion in 
the DJ-1 gene in dementia patients. This gene was identified in patients with Parkin-
son’s disease in the GRIP study. Finally, Chapter 4 provides a general discussion of  
the work presented in this thesis and provides suggestions for future research in AD.
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Abstract
Alzheimer’s disease (AD) is the most common cause of age-related dementia. AD 
is characterized by a strong familial aggregation. However, the genetic origin of 
AD is partly understood. We conducted a genome screen in late onset AD pa-
tients from a young, genetically isolated population from the Southwest of the 
Netherlands. Extensive genealogy was collected, resulting in an extremely large 
and complex pedigree including 4,645 members and 103 patients. For parametric 
linkage analysis the pedigree was split into 35 families in which the number of 
patients is maximized under a family size restriction of maximal 35 bits. This set of 
sub-pedigrees preserved 87.5% kinship of the patients.
All patients and their 170 closely related relatives were genotyped using 402 mic-
rosatellite markers. Simulation analyses suggested that parametric linkage analysis 
using these sub-pedigrees requires a stringent significance threshold: a LOD of 
3.64 corresponds to 5% genome-wide type-I error. The subsequent genome screen 
multipoint analysis yielded 8 regions with HLOD > 2, which were fine mapped 
with 45 additional markers. After the fine mapping, four loci were significantly 
linked and one was suggestively linked to AD.
The strongest evidence of linkage was for chromosome 1q21 (HLOD = 5.20, at 
marker D1S498), which is a locus identified earlier. We confirmed the AD locus 
at 10q24 (HLOD = 4.15, at marker D10S185). There is also significant evidence 
of linkage at chromosomes 3q23 (HLOD = 4.44 at marker D3S1569) and 18q12 
(HLOD = 3.68, at marker D18S1152). Several single families contributed strong 
linkage signals on chromosomes 1, 3 and 18. Multiple families contributed moder-
ate linkage signal to chromosome 10q24 locus. Finally, there is also suggestive 
evidence of linkage at chromosome 11q24 (HLOD = 3.29, at marker D11S1320).
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that accounts 
for the vast majority of age-related dementia. The population prevalence of the 
disease rises steeply with age from below 2% at 65 years to above 35% after the age 
of 90 [1, 2]. Family history is an important risk factor for AD and in a large number 
of families the disease segregates as a dominant trait. A recent large twin study con-
firmed that the heritability for AD was up to 79% [3]. Several dominant mutations 
for AD genes have been identified including mutations in the presenilin 1 (PSEN1) 
gene [4], presenilin 2 gene (PSEN2) [5, 6], and Amyloid Precursor Protein (APP) 
gene [7]. A common polymorphism (e4) in the gene encoding apolipoprotein E 
(APOE) increases susceptibility to both early and late onset AD [8].
All these four genes together explain less than a quarter of the disease prevalence, 
indicating additional genetic risk factors remained to be identified [9, 10]. In ad-
dition to APOE, more than three dozens of candidate genes were reported to be 
associated with late onset AD. None of these, however, has been consistently repli-
cated [11, 12]. Furthermore, genome screens targeting AD loci were conducted. As 
reviewed by the AlzGene database, the replicated regions from previous genome 
screens include: 1p36, 1q21-31, 2p23-24, 4q35, 5p13-15, 6p21, 6q15-16, 6q25-27, 
9p21-22, 10q21-22, 10q25, 12p11-12, 19q13, 21q21-22, and Xp11-21 [13-28].
Loci for the established genes for AD (APP, PSEN1, PSEN2 and APOE) have 
been initially localized by linkage analysis. Pedigrees suitable to localize genes, 
however, have become scarce particularly for late onset and sporadic familial 
diseases. Genetically isolated populations provide excellent material for linkage 
analysis. Using genealogical records, extended pedigrees can be constructed. This 
method has been used successfully in Iceland [29, 30]. We have followed this ap-
proach in a genetically isolated community from the Southwest of the Netherlands, 
where church and municipal records were used to connect patients with late onset 
AD [31]. A total of 103 late onset AD patients were connected into a large pedigree. 
In this paper, we present the results of a linkage based genome wide screen in these 
patients.
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Material and Methods
Population & Genealog y
This study was performed within the framework of the previously described 
Genetic Research in Isolated Populations (GRIP) program [32-34]. The Medical 
Ethics Committee of the Erasmus MC approved GRIP protocols. The GRIP 
population is a genetically isolated community in the southwest of the Netherlands. 
Less than 400 individuals founded the population in the middle of the 18th cen-
tury. Considerable population growth subsequently occurred. Until recently, there 
was minimal immigration. An estimated 20,000 descendants of this population 
are now scattered over eight adjacent communities. The genealogical database cur-
rently contains information on more than 90,000 people spanning 23 generations. 
Residents in the GRIP area are generally related via multiple lines of descent and 
inbred via multiple consanguineous loops.
Patient ascertainment
Patients with AD were traced through general practitioners, neurologists and 
nursing-home physicians. The diagnosis of AD was verified by two independent 
neurologists according to the NINCDS ADRDA criteria [35], and then re-evalu-
ated by a research physician and a research neurologist. Data on the presence of 
AD, parkinsonism, essential tremor and dementia were collected in first, second 
and third-degree relatives by means of a family-history questionnaire. First-degree 
relatives also underwent a brief neurological examination. All patients and their 
relatives who were invited to participate in this study provided informed consent. 
A total of 112 probable late onset AD patients (age of onset greater than 65 years, 
mean age of onset = 75 ± 5.3 years) and 170 unaffected relatives were ascertained.
Genotyping
For all patients and their 170 first-degree relatives, DNA was extracted from 
peripheral leucocytes following a standard protocol [36]. Mutations in the APP, 
PSEN-1 and PSEN-2 genes were previously excluded [31]. The APOE genotype 
was determined on all DNA samples using TaqMan allelic discrimination technol-
ogy on an ABI Prism 7900HT Sequence Detection System with SDS V 2.1 (Applied 
Biosystems, Foster City, CA). Patients and their first-degree relatives underwent a 
full genome-screen in two sequential experiments. Both screens were conducted 
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using the same set of micro-satellite markers, evenly spaced by approximately 10 cM 
(ABI Prism Linkage Mapping Set MD-10 Versions 2 and 2.5, Applied Biosystems, 
Foster City, CA, USA). Polymerase chain reactions (PCR) were performed according 
to the manufacturer’s specified conditions. PCR products were separately pooled 
and analyzed on ABI377 and ABI3100 automated sequencers (Applied Biosystems). 
Results were pooled using the maximum likelihood method [37]. Two independent 
technicians read the results from the sequencers; a third reader resolved the dis-
cordant results. Only the markers with the discordance proportion less than five 
percent were selected for further analysis. A total of 402 markers with missing 
rates less than 5% were included from the initial scan. Regions linked to late onset 
AD were later fine typed by placing additional 45 markers in between those from 
the initial set at a distance of one to five cM apart.  Genotyping errors leading 
to Mendelian inconsistencies were detected using PedCheck [38]. Unlikely double 
recombination events were detected using Merlin [39]. Definitive genotyping errors 
and unlikely genotypes were rechecked using the data from the laboratory.
Pedigree splitting
To split this large pedigree we used a graph theory approach based on the maximal 
cliques partitioning, which was successfully applied for pedigree splitting by Falchi 
et al  [43]. This method has been successfully applied in identification of new locus 
for hypertension [44]. We modified this method by setting the requirement that the 
resulting sub-pedigrees should have no more than a user-specified bits-size, where 
the bit-size is computed as  (2 * number of founders – number of non-founders). 
Our software is allows a variable number of relatives to be included in the sub 
pedigrees. It is freely available at http://mga.bionet.nsc.ru/nlru/.
Evaluation of Type-I error rate
Breaking pedigrees may increase the possibility of spurious linkage findings in pa-
tients where multiple distant lines of descent are present and ignored after breaking 
the pedigree [40]. Therefore we estimated the threshold for statistical significance 
using simulations. 
To evaluate genome-wide type-I error we simulated our genome scan 100 times. 
We used the complete pedigree including all 4,645 members for marker simulation 
by dropping unlinked markers down through the pedigree. Number of markers, 
intermarker distances and maker allele frequencies were simulated according to 
the typed markers. After each gene-dropping experiment, we performed linkage 
analysis using the derived sub-pedigrees where disease allele frequency, liability 
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classes, genetic model and penetrances were the same as we used later in the actual 
linkage analysis. Genotypes of untyped individuals were set to missing. For each 
genome-screen the highest HLOD score was stored. Cumulative density function 
of the obtained 100 maximal HLOD scores approximates the distribution of ge-
nome-wide type-I error rates. 
Linkage and Haplotype analysis
In linkage analysis, we assumed a dominant model of inheritance with age depen-
dent penetrance. Seven liability classes were defined based on age (years): <65, 
65-69, 70-74, 75-79, 80-84, 85-90, and >90. For each age group j, age dependent 
population prevalence,      , was obtained from the Rotterdam Study [1]. The disease 
gene penetrance,      of the jth age group can be estimated:
where PAF stands for the population-attributable fraction, the proportion of the 
population prevalence that can be explained by the studied gene (10% assumed), 
and q is the disease allele frequency (1% assumed). The estimated penetrance 
for each defined age group is shown in Supplementary Table 1. Marker allele 
frequencies were estimated based on 144 chromosomes from unaffected elderly 
GRIP population members. For small pedigrees (bits ≤ 18), we used the exact 
calculation of multi-locus likelihood, Lander-Green algorithm implemented in 
GENEHUNTER 2.0 [45]. For larger pedigrees, we used Markov chain Monte 
Carlo estimation methods implemented in SIMWALK 2.91 [42, 46, 47]. Overall 
LOD scores and Heterogeneity LOD (HLOD) scores were computed by combin-
ing per family results from the two packages using standard formulas below.
where maxLR is maximized with respect to    , the proportion of the linked families, 
yielding Maximum Likelihood Estimate     ,
Haplotypes were reconstructed based on the genotypes of patients, spouses of 
patients and their offspring using MERLIN package [39]. Haplotypes are shown 
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only for the linked families with the highest LOD scores. These families are fur-
ther expanded in order to depict the haplotype sharing of other patients who are 
relatively closely related to the patients in these families.
Association testing
We tested for association six markers on chromosome 3 and four markers on 
chromosome 18 where we found that 2 haplotypes of these regions were shared by 
multiple patients from the same family. We used the 112 patients as cases and their 
35 age-matched, unaffected spouses as controls, for whom we had both phenotypic 
and genotypic information. The CC-QLS test proposed by Bourgain et al. was used 
to test for association adjusting for the inter-relationships among the samples.
Results
By tracing the genealogy of the 112 probable late onset AD patients, we connected 
103 patients to a single pedigree containing 4,645 individuals in 18 generations 
as depicted in figure 1. The other 9 patients were singletons and, therefore, were 
not included in the linkage analysis. This large pedigree showed multiple, distant 
lines of descent and consanguineous loops (table 1). The average kinship coefficient 
among patients was 0.0018. This value is in between a 3rd cousin once removed 
and a 4th cousin. Utilizing such a pedigree in linkage analysis is computationally 
challenging. Using the described algorithm we clustered all patients and 170 first-
degree relatives, into 35 sub-pedigrees (supplemental figure 2). These sub-pedigrees 
contained a total of 1,227 individuals, of whom 630 (51.3%) were female (table 1). 
We estimated the threshold for statistical significance using simulation analysis. 
Our simulations show that a HLOD score of 2.11 corresponds to a genome-wide 
type-I error rate of 50% (suggestive linkage) and HLOD of 3.64 corresponds to a 
genome-wide type-I error rate of 5% (significant linkage) (supplementary table 2).
Multipoint LOD and HLOD score plots for the initial scan are shown in supple-
mentary figure 1. A total of eight regions showed suggestive linkage. These were 
fine typed with 45 additional markers, including: chromosome 1 (14 additional 
markers), chromosome 3 (10 additional markers), chromosome 5 (2 additional mark-
ers), chromosome 6 (5 additional; markers), chromosome 7 (3 additional markers), 0 
(6 additional markers), chromosome 11 (2 additional markers), and chromosome 18 
(3 additional markers). Table 2 summarizes the results of fine mapping. After fine 
mapping, we confirmed two regions linked to late onset AD on chromosomes 1
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Figure 1. The entire pedigree contains 103 late onset AD patients and 4,645 rela-
tives. Men are represented with squares and women with circles. Black dots rep-
resent marriage nodes. Affected individuals are represented with the dark squares 
and circles. Unknown affection status is represented with grey. For simplicity, 
unaffected relatives of the patients are not shown.
(figure 2A) and 10 (figure 2C). The maximum HLOD at 1q21 was 5.2 at D1S498. 
On chromosome 10, the maximum HLOD score was 4.2 at D10S185. There is also 
suggestive evidence for linkage on chromosome 11 (HLOD = 3.3 at D11S1320, 
figure 2D). In addition to the confirmed regions, we found significant linkage for 
a region on chromosome 3 that spanned 18 cM from marker D3S3514 to D3S3626, 
and reached a maximum HLOD of 4.4 at marker D3S1569 (figure 2B). This is the 
second highest peak over the genome. We also found significant linkage for a new 
region on chromosome 18 (HLOD = 3.7 at marker D18S1152, figure 2E).
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Table 1. Genealogic characteristics of 103 LOAD patients and their relatives
Haplotype analysis showed that two haplotypes on chromosome 1 segregate in 
different families. On chromosome 1q21, a 15 cM region shared by 4 patients in 
family A and 6 other closely related patients (Figure 3A). The haplotype of the 
second region on chromosome 1q24 spans 21 cM that segregates in family B and is 
shared by other four closely related patients (Figure 3B). The haplotype on chromo-
some 3q23 (18 cM) segregates in some individuals together with the haplotype on 
  
  
  

  

 ± 
× ± 

  

 ± 
× ± 
  
  
  
  
  
  
  

  
  
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chromosome 18q12 (15 cM) (Figure 3C and 3E). In total 6 patients from families 
C and E carry both haplotypes. The LOD score from the region on chromosome 
10 was based on moderate contributions from multiple families, and, thus, the 
haplotype segregation is not as obvious as other linked regions. The haplotype of 
the region on chromosome 11 is shared by 4 patients and 2 other closely related 
patients  (Figure 3 D).
 
Finally, we tested for association between AD and 6 markers of chromosome 3 and 
4 markers of chromosome 18. Association was detected between marker D3S3607 
and AD being borderline significant (p-value = 0.05). 
Discussion
In this study we confirmed earlier findings suggesting linkage of a wide region on 
chromosome 1q21-31. This region was initially associated with late onset AD in a 
genome screen using samples of brain tissue from 50 autopsied AD patients and 50 
autopsied controls [24]. A genome-screen in Finland reported linkage to the 1q24.2 
region, where the marker D1S1679 was associated with late onset AD [25]. Finally, 
a genome-scan examined 437 families from the National Institute of Mental Health 
(NIMH) showed significant evidence for linkage of AD to the 1q23 region [48]. 
Also our study shows significant evidence of linkage to 1q21 and 1q24. The 1q21 
region yielded the most significant evidence of linkage over the genome in our 
study (HLOD = 5.2). This region contains the gene encoding niscatrin (NCSTN), 
which binds presenilin and is required for γ-secretase activity and Aβ generation 
[49]. Mutations in this gene have been found to be related to early onset AD and we 
have reported association in a sub-group of patients with familial early onset AD, 
particularly in those who lack the APOE*4 allele  [57]. We sequenced all the exons 
and intron/exon boundaries of this gene, but have not found variants. Another 
candidate gene in this region is the gene encoding C-reactive protein (CRP), which 
acts as a scavenger for chromatin released by dead cells during the acute inflamma-
tory process [50]. We also sequenced the exons and intron/exon boundaries of this 
gene in 7 patients (4 from family 1 and 3 closely related to family 1) and we found 
2 variants, SNPs rs1130864 and rs1417938 segregating with 6 of the 7 patients. 
Interestingly, SNP rs1130864 has been reported as a tagging SNP for a haplotype 
associated with higher levels of CRP [51, 52].
The second highest linkage signal following chromosome 1q21 region was found 
at chromosome 3q23. This region was reported to be linked to AD without tau 
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Table 2. Summary of LOD and HLOD scores for regions with significant or sug-
gestive linkage after fine typing
1 Overlaps with regions reported with suggestive linkage or significant association 
in previous genome screens, including: A (Zubenko et al. 1998), B (Poduslo et 
al. 1999), C (Curtis et al. 2001), D (Hiltunen et al. 2001), E (Olson et al. 2002), F 
(Myers et al. 2002), G (Blacker et al. 2003), H (Farrer et al. 2003), and I (Holmans et 
al. 2005). Note that B screened for only 2 chromosomes. LOD and HLOD scores 
with a genome-wide Type I error rate < 0.05 are in bold
pathology, earlier in a study of a small family with 4 relatives [53]. A significant 
LOD score of 4.1 between markers D3S1569 and D3S3554 was reported where the 
marker D3S1569 is the same marker in our study that gives the maximum HLOD 
over chromosome 3. In the study of Poduslo et al (1999), no genome wide screen 
was conducted but only chromosomes 3 and 17 were screened since the disease was 
expected to be related to frontotemporal dementia. As we do not have pathology 
information of our patients, we cannot exclude that part of our patients also suf-
fer from this atypical form of AD. Furthermore, this region also shows evidence 
for association to AD in our study. The linked region on chromosome 3 includes 
obvious candidate genes including the transferrin gene, the gene encoding for 
butyrilcholinesterase, the neprilysin gene and the somatostatin gene. We screened 
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  
      
      
      
      
      
      
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Fig 2. Multipoint LOD (dark) and HLOD (light) scores for chromosomes 1, 3, 10, 
11, and 18 in the genome screen of late onset Alzheimer’s disease after fine typing. 
Marker locations are given in Kosambi centi-Morgans.
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these genes for mutations but no variants were found. We are currently sequencing 
more genes in this region.
Our results for chromosome 10q24 are consistent with previous findings. An af-
fected sib-pair analysis using the NIMH sample [13] suggested linkage to chromo-
some 10p11-q26. A second stage analysis adding additional affected sib-pairs and 
genetic markers, increased the multipoint LOD score to 3.5 [18]. This same region 
was linked to plasma amyloid β42 levels with a LOD of 3.9 [54]. Using part of the 
initial NIMH sample, three recent genome-screens also pointed to the same region 
(10q21-24) [19, 20, 23]. The region linked to late onset AD in our study (10q24) is 
the first replication using a fully independent data set from the NIMH sample. 
We also found suggestive evidence for linkage on chromosome 11q24. Blacker et 
al (2003) [20] previously described this region in their study of the NIMH sample, 
including 437 families with AD.
In our study, chromosome 18 is significantly linked to AD and to our knowledge 
no candidate gene close to this region has been previously reported in relationship 
with AD. Linkage of AD to chromosome 18q has been previously reported to a 
narrow region around 112cM with a multipoint LOD score of 3.37 for D18S541 [55]. 
This region is 23 cM downstream from our peak. However, for the chromosome 18 
E. Chromosome 18
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region there is substantial heterogeneity with some families showing negative LOD 
scores. When testing for association, no evidence of association was found. Since 
there is a clear overlap in patients (n=6) sharing both the chromosome 3 and 18 
haplotypes, it remains to be determined whether one of the two findings is a false 
positive. This requires sequencing of all genes in both regions. Alternatively, these 
two regions may be involved in the onset of AD with epistatic effects.
In this study it was necessary to split the extended complex pedigree into small sub-
pedigrees for computational reasons. We used an approach for splitting proposed 
by Falchi et al [43]. In order to optimize the key parameters required by the method 
of Falchi and to obtain a set of sub-pedigrees which can be efficiently analyzed 
using currently available software for parametric linkage analysis, we restricted our 
splitting on maximum bit size and iterated over all the required parameters to find 
out the best set of sub-pedigrees. Since breaking pedigrees may increase false posi-
tives we adjusted our thresholds for linkage based on simulation analysis.
In summary we confirmed two previously well described linkage regions for late 
onset AD on chromosomes 1q21-25 and 10q24. This is the first genome-wide 
screen that showed significant linkage to chromosome 3q23 markers. We also 
found significant linkage to a new locus at chromosome 18q12.
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Fig 3. Haplotypes of chromosomes 1, 3, 11 and 18 segregating with AD families 
from the GRIP population.
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Supplementary Table 1. Age dependent liability classes and penetrances
1 Population prevalence was obtained from the Rotterdam Study (Ott et al. 1995).
Supplementary Table 2. LOD score and corresponding Type I error, based on 
100 genome-wide simulations.
LOD HLOD Type I error 
4.08 4.08 1% 
3.56 3.63 5% 
3.24 3.24 10% 
2.02 2.11 50% 
Liability Class Age (years) Population Prevalence1 Penetrance 
Number of AD 
patients 
Number of genotyped unaffected 
relatives 
1 < 65  0.00 0 129 
2 65-69 0.02 0.09 4 6 
3 70-74 0.05 0.23 22 11 
4 75-79 0.09 0.46 32 14 
5 80-84 0.23 0.99 30 8 
6 85-89 0.35 0.99 24 1 
7 >=90 >0.35 0.99 0 1 
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Supplementary Fig 1. Multipoint LOD and HLOD scores for each autosome in 
the genome screen of late onset Alzheimer’s disease before fine typing. Marker 
locations are given in Kosambi centimorgans (cM).
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Supplementary Fig 2. The 35 sub-pedigrees obtained by applying the cluster-
ing algorithm to the entire pedigree. Affected individuals are shown with b;lack 
squares and circles, unaffected first-degree relatives of the patients, ancestors from 
the patients and relatives are shown with grey squares and circles.
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The MAPT and Granulin 
genes are not associ-
ated with Alzheimer’s 
disease
48
Abstract
The microtubule associated protein tau plays a pivotal role in Alzheimer’s disease 
(AD) pathogenesis but findings on the MAPT gene, encoding for the tau protein, 
have been controversial. The discussion about the role of this gene was recently fu-
elled by the identification of new MAPT haplotypes associated with AD and a new 
gene, granulin (GRN) 1.4 Mb upstream of MAPT associated with fronto-temporal 
dementia. We have investigated the association between AD and the region includ-
ing MAPT and GRN in patients from the Genetic Research in Isolated Populations 
(GRIP) program. We studied 122 AD patients and 85 control subjects using an 
extensive Single Nucleotide Polymorphism (SNP) panel. No association was found 
for any individual SNP of the MAPT gene, H1/H2 haplotype, or H1c haplotype 
sub-clade. The interaction with APOE*4 was considered by stratified analysis but 
no evidence for association was found. Also, the MAPT gene was excluded by 
linkage analysis. We also performed a meta analysis of all studies conducted to date 
on the associations between the MAPT gene and AD stratified by APOE*4. The 
meta analysis showed a very modest non-significant association (OR = 1.20, 95% 
CI 0.93-1.55) for carriers of the H2 haplotype compared to H1/H1 carriers, only in 
those with the APOE*4 allele. Nominally significant association was found for two 
SNPs located 722 kb upstream the MAPT locus in the NMT1 gene, but findings 
did not sustain adjustment for multiple testing. The GRN gene was sequenced in 
17 patients of families showing evidence of linkage to this region but no mutations 
were found. These results suggest that variations in the MAPT gene and other 
genes in the region including GRN have little or no effect with Alzheimer’s disease 
in our population.
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Introduction
Alzheimer’s disease (AD) is a complex genetic disorder, which is characterized 
by amyloid deposition and hyperphosphorylation of the microtubule associated 
protein tau in the brain [1, 2]. Several genes have been implicated in the dominant 
form of early onset AD including the amyloid precursor protein gene (APP) [3], 
presenilin-1 (PSEN-1) [4-8], and presenilin-2 (PSEN-2) [9, 10]. The e4 allele of 
APOE gene has been associated with early and late onset AD [11, 12]. Follow up 
studies have shown that individuals carrying one copy of this allele have a 1.5-2 
fold increase of risk of the disease and those carrying two copies have a 6-15 fold 
increase of risk [1, 13]. Each of these 4 genes is implicated in the amyloid pathology 
involved with AD rather than to the tau pathology characteristic of AD.
Despite the fact that the microtubule associated protein tau plays a key role in 
AD, findings on the gene encoding for the tau protein (MAPT gene ID:4137) are 
inconsistent. While specific mutations and polymorphisms in this gene are known 
to lead to several tauopathies including fronto-temporal dementia, progressive su-
pranuclear palsy, corticobasal degeneration, and argyrophilic grain disease [14, 15], 
the relationship between MAPT polymorphisms and AD remains controversial 
[15].
In brains of AD patients, the tau protein is hyperphosphorylated, truncated, and 
aggregated into neuro fibrillary tangles (NFTs). In vitro studies suggest that the 
tangle formation is partially controlled by the tau protein itself [16]. The MAPT 
gene is located on chromosome 17q21.1 and in the human brain it codes for 6 
different isoforms, which contain 12, 11, 10, or 9 exons due to complex alternative 
splicing. Some studies found association of polymorphisms in MAPT with AD [17, 
18]. The new Single Nucleotide Polymorphism (SNPs)  of the MAPT gene identi-
fied in the HapMap project [24] and other sequencing efforts have generated new 
opportunities to study this gene in depth. However, these findings have not been 
consistent with five studies failing to support association of MAPT to AD [19-23]. 
There is some evidence for modification of the effect of MAPT by APOE but these 
findings have also been inconsistent. Three studies found an association between 
MAPT and AD in APOE*4 carriers [17, 25, 26] indicating a possible interaction 
between the APOE gene and the tau protein. In contrast, the H1c variant of the 
H1 haplotype was over represented in AD cases without the APOE*4 allele [27]. 
Finally, mutations in the granulin (GRN) gene, located 1.4Mb upstream of MAPT 
[28, 29] and leading to frontal lobe dementias, may explain the association between 
the MAPT region and AD.
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We investigated 43 SNPs spanning a 1.85 Mb region including the MAPT and 
GRN genes in an extended family-based study including 122 AD patients, allowing 
both linkage and association analyses [30, 31]. We further evaluated the interaction 
between MAPT SNPs and the APOE*4 allele.  Since studies of interaction require 
large numbers of patients and controls, we evaluated the evidence for the interac-
tion between the APOE gene and the MAPT haplotypes in a meta-analysis of all 
studies published to date. 
Materials and Methods
Study population
AD patients (n=122) and their relatives were derived from a study of dementia, 
performed within the Genetic Research in Isolated Populations (GRIP) study [32]. 
The GRIP population is a genetically isolated community in the Southwest of The 
Netherlands. This community expanded from a founding population of about 150 
ancestors to a current number of approximately 20,000 inhabitants. Since there has 
been little inward migration, a genetically homogeneous population arose from 
the founder population. In this isolate, all patients with dementia were ascertained 
through local general practitioners, neurologists and nursing-home physicians. 
Genealogy data up to 23 generations was collected for all patients. Clinical di-
agnoses of AD were confirmed by an independent neurologist according to the 
NINCDS-ADRDA criteria [33]. Control  individuals  were  ascertained  from  the 
1
AD patients Controls 
Number 122 85 
Mean age at onset (years) 75.0 - 
Female (%)* 94(76.4) 44(51.8) 
Average Kinship* 0.001953 - 0.000977 0.000488 - 0.000244 
APOE*4 carriers (%)* 72/116(62.1) 30/85 (35.3) 
Table 1. Description of cases and controls
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GRIP population. Informed consent was obtained from first-degree relatives or 
spouses and the patient if possible. The Medical Ethical Committee of the Erasmus 
Medical Center approved the study protocol. More detailed descriptions of the 
clinical diagnosis re-evaluation and genealogy data retrieval can be found in our 
previous report [32].
Genotyping
Blood was drawn from patients and their first-degree relatives. DNA was extracted 
from peripheral leucocytes according to a standard protocol [34]. A total 43 of SNPs 
spanning a 1.9 Mb region around the tau gene on chromosome 17 were selected, 
with an average distance of 40.5 kb between adjacent SNPs. The selection of the 
SNPs for this study was based on their physical location in the MAPT gene and 
its flanking region. 10 SNPs were located in the gene’s transcriptional region. SNP 
genotyping was performed using a SNPlex assay (Applied Biosystems). The SNPlex 
assay was conducted following the manufacturer’s recommendations (Applied 
Biosystems, Foster City, CA). Stock genomic DNA (gDNA) solutions (50 ng/μl) 
were diluted after fragmentation to a final concentration of 18.5 ng/μl. Diluted 
gDNA aliquots (2 μl) were spotted and dried down in 384 well plates (Bioplastics). 
Prior to the oligo ligation assay (OLA) reaction, reagents were phosphorilated and 
diluted (1:1). The OLA reaction was performed in 5 μl volumes, which contained 
37 ng of gDNA, (0.5 μl) ligation buffer, (0.025 48-SNPlex ligase and (l μl) activated 
ligation probe pool). The PCR conditions were: 3 minutes at 90°C, 30 cycles of 15 
seconds at 90°C, 30 seconds at 60°C and 30 seconds at 51°C (2% ramp), followed by 
denaturation step at 99°C for 10 minutes. After this step, a purification (digestion) 
step was conducted after which OLA products were ready to be amplified in a final 
volume of l0 μl. Exonuclease I (4l μl) and Lambda Exonuclease (82 μl) (Applied 
Biosystems) were added, and incubated first at 37°C for 90 minutes and then at 
80°C for 10 minutes. Purified OLA products were diluted (2:3) for further ampli-
fication. Amplification of OLA products was performed in l0 μl volumes, which 
contained 2 μl of diluted OLA reaction, (Ix) SNPlex amplification master mix and 
(20x) SNPlex amplification primers. The OLA amplification conditions were: 95°C 
for 10 minutes, followed by 95°C for 15 seconds, 63°C for 60 seconds for 30 cycles. 
After hybridization step, analysis of the fluorescence intensity was performed in 
an aliquot (7.5 μl) using ABI Sequencer 3730 (Applied Biosystems, Foster City, 
CA). All pre-PCR steps were performed on a cooled block. Reactions were carried 
out in Gene Amp 9700 Thermocycler (Applied Biosystems, Foster City, CA). Data 
was analyzed using Genemapper v3.7 (Applied Biosystems, Foster City, CA). The 
APOE genotypes were determined on 5 ng/ul dry DNA samples using TaqMan 
allelic discrimination technology on an ABI Prism 7900HT Sequence Detection 
System with SDS v 2.1 (Applied Biosystems, Foster City, CA). All samples were 
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Table 2. Description of the 37 SNPs studied
Marker Position rsnumber Gene Location: 
1 hCV2536908 40526680 rs7219596 NMT1 exon 4* 
2 hCV341577 40538554 rs1053733 NMT1 3' UTR 
3 hCV9254243 40571807 rs4986172 ACBD4 intron 7 
4 hCV2032862 40598477 rs11657325 FLJ32384 intron 1 
5 hCV2032865 40603713 rs7208548 Intragenic -
6 hCV2554844 40717672 rs2074291 MAP3K14 intron 5 
7 hCV2541205 40828104 rs1059504 LOC201176 3' UTR 
8 hCV2265271 41070456 rs241039 LOC401884 3' UTR 
9 hCV2544843 41235818 rs110402 CRHR1 intron 1 
10 hCV2257689 41241147 rs242924 CRHR1 intron 2 
11 hCV2544830 41256855 rs173365 CRHR1 intron 4 
12 hCV2257669 41301901 rs1078830 Intragenic -
13 hCV7450857 41340226 rs1467966 MAPT 5' UTR 
14 hCV3202946 41350591 - MAPT 5' UTR 
15 hCV3202949 41352389 rs1560313 MAPT 5' UTR 
16 hCV1016016 41375573 rs242557 MAPT 5' UTR 
17 hCV3202956 41381748 rs242559 MAPT 5' UTR 
18 hCV7563692 41407682 rs1800547 MAPT intron 3 
19 hCV3202960 41424176 rs2435214 MAPT intron 5 
20 hCV2042903 41424329 rs11656151 MAPT intron 5 
21 hCV11936104 41439239 rs1991556 MAPT intron 7 
22 hCV2560317 41461242 rs7521 Intragenic -
23 hCV2264293 41465690 rs1078997 LOC284058 intron 12 
24 hCV2560314 41472690 rs16940845 LOC284058 intron 7 
25 hCVl1936132 41497167 rs2838 LOC284058 intron 5 
26 hCVl5858203 41511550 rs2066899 LOC284058 intron 3 
27 hCV7563831 41551932 rs1468241 KIAA1267 intron 1 
28 hCV2560260 41560151 rs2016730 KIAA1267 intron 2 
29 hCV338624 41604276 rs2240758 KIAA1267 exon 1* 
30 hCV2598655 41615467 rs2240756 Intragenic -
31 hCV2554114 42150418 rs142167 NSF intron 15 
32 hCV2261778 42164185 rs199448 NSF intron 6 
33 hCV2261785 42184098 rs199533 NSF exon 8* 
34 hCV2261819 42220763 rs199498 WNT3 intron 1 
35 hCVl1623713 42227151 rs111769 WNT3 intron 1 
36 hCVl139279 42248220 - Intragenic -
37 hCV2275279 42372240 rs758391 GOSR2 5'UTR 
Position: position in bp of each SNP, SNP names in italics show the SNPs located on 
the MAPT gene and on its 3 kb-flanking region, *: Indicates a SNP that generates 
a synonymous change
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 MAF Single SNP 
2SNPs
haplotype
3SNPs
haplotype
Marker Cases controls P P P
1 hCV2536908 0.2371 0.2099 0.509 0.334 0.046
2 hCV341577 0.4454 0.4146 0.508 0.017 0.044
3 hCV9254243 0.3683 0.3736 0.954 0.206 0.084
4 hCV2032862 0.233 0.2813 0.262 0.013 0.028
5 hCV2032865 0.4187 0.4999 0.094 0.120 0.532
6 hCV2554844 0.4968 0.4938 0.890 0.949 0.978
7 hCV2541205 0.4708 0.4389 0.571 0.778 0.664
8 hCV2265271 0.1755 0.2126 0.384 0.264 0.272
9 hCV2544843 0.4495 0.3671 0.109 0.153 0.360
10 hCV2257689 0.459 0.3671 0.074 0.288 0.470
11 hCV2544830 0.446 0.4631 0.766 0.736 0.610
12 hCV2257669 0.1837 0.2049 0.643 0.859 0.702
13 hCV7 450857 0.1887 0.235 0.288 0.287 0.431
14 hCV3202946 0.1347 0.1357 0.930 0.763 0.348
15 hCV3202949 0.4547 0.4368 0.690 0.130 0.347
16 hCV1016016 0.383 0.3536 0.597 0.550 0.650
17 hCV3202956 0.1863 0.2346 0.261 0.368 0.336
18 hCV7563692 0.1808 0.2135 0.443 0.450 0.411
19 hCV3202960 0.1695 0.1446 0.463 0.461 0.245
20 hCV2042903 0.2682 0.3078 0.396 0.189 0.414
21 hCV11936104 0.1734 0.2376 0.131 0.158 0.152
22 hCV2560317 0.4803 0.4819 0.946 0.784 0.982
23 hCV2264293 0.194 0.2194 0.497 0.669 0.315
24 hCV2560314 0.4335 0.4405 0.867 0.507 0.482
25 hCVl1936132 0.1745 0.2074 0.442 0.629 0.180
26 hCVl5858203 0.1912 0.2188 0.544 0.650 0.366
27 hCV7563831 0.1776 0.2084 0.467 0.281 0.252
28 hCV2560260 0.1659 0.125 0.243 0.338 0.368
29 hCV338624 0.1565 0.1125 0.193 0.208 0.152
30 hCV2598655 0.1543 0.1325 0.510 0.450 0.162
31 hCV2554114 0.2083 0.2013 0.801 0.149 0.596
32 hCV2261778 0.1703 0.2013 0.479 0.478 0.298
33 hCV2261785 0.1733 0.2049 0.469 0.566 0.520
34 hCV2261819 0.174 0.2063 0.411 0.414 0.398
35 hCVl1623713 0.3827 0.45 0.191 0.594 0.372
36 hCVl139279 0.2389 0.1976 0.329 0.790 -
37 hCV2275279 0.4759 0.475 0.998 - -
MAF: Minor allele frequency, p: nominal p values from CC-QLS test, (X) SNPs 
haplotype: haplotype-wise case-control comparison by CC-QLS. Bold P values 
indicate nominally significant  CC-QLS p values.
Table 3.  Comparison of the SNP allele frequencies between cases and controls
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genotyped using 15 flourescently labelled microsatellite markers from chromosome 
17 which were, on average, 10 centimorgans apart (ABI Prism Linkage Mapping Set 
MD-10 Versions 2.5, Applied Biosystems, Foster City, CA, USA). The genotyping 
experiments were done following manufacturer instructions (Applied Biosystems, 
Foster City, CA).
Mutation Screening
Mutations in the APP, PSEN-1 and PSEN-2 genes were previously excluded [32]. 
For mutation screening, of the GRN gene, sequences were obtained from the 
UCSC database (http://genome.ucsc.edu/) assembly March 2006. A touchdown 
PCR was designed to amplify all the amplicons. Direct sequencing of both strands 
was performed using Big Dye Terminator V 3.0 chemistry (Applied Biosystems). 
Fragments were loaded on an ABI 3100 automated sequencer and analysed with 
DNA Sequencing Analysis V 3.7 and SeqScape V 2.5 packages (Applied Biosystems). 
Information on amplicons, primers, and size of fragments is available on request.
Statistical Analyses
Genotyping errors leading to Mendelian inconsistencies were screened using Mega2 
[35] and PedCheck [36]. To identify unlikely double recombination events on the 
same chromosome we used the Merlin package [37]. We used the exact test imple-
mented in HAPLOVIEW [38] to examine whether genotype and allele proportions 
were in Hardy-Weinberg equilibrium. Only those SNPs that had genotype data 
available for more than 90% of all samples, and that the genotype proportions were 
in Hardy-Weinberg equilibrium in controls (p>0.05) were selected for the analysis. 
The haplotype block structure of the MAPT region was determined using 
HAPLOVIEW. Linkage disequilibrium (LD) blocks were defined using the 
Gabriel method [39]. The SNP hCV7563692 which is in LD (r2>0.96) with the 
H1 haplotype tagging SNP [40], was used to infer the H2/H1 haplotype. The Hlc 
haplotype, which has been recently associated with AD [27], was inferred by the 
combination of the hCV1016016 and hCV2560317 SNPs. In order to test differences 
in the extent of LD between cases and controls, we applied the LD contrast test 
[41]. Briefly, this test provides a comparison of pair wise matrices of LD between 
cases and controls. Haplotypes were estimated for all SNPs and sliding windows of 
two and three adjacent SNPs using the program PHASE 2.0 [42, 43].
The Quasi-Likelihood Score (QLS) test of the CC-QLS package [44] was used for 
the association analysis to correct for relationships between patients. For the CC-
QLS test, kinship and inbreeding coefficients were calculated using our genealogy 
Chapter 2.2. The MAPT and GRN genes and AD
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database. For those individuals whose genealogy was not available, the average 
kinship and inbreeding coefficients were used. False-positive linkage peaks may 
result from linkage disequilibrium among tightly linked SNPs [45] therefore, we 
selected tagging SNPs for the linkage analysis which showed a pair wise D’ value 
of less than 0.4. Linkage analysis was conducted using SimWalk2 V.2.91 [46-48]. 
Parametric linkage analysis was performed under a dominant model. Age dependent 
penetrance was estimated based on population prevalence [49]. The disease gene 
frequency was set to one percent. Allelic frequencies for microsatellite markers 
were estimated from unrelated controls.
Meta Analysis
We performed an internet search through the Alzheimer Research Forum (ARF) 
web page (http://www.alzforum.org/) [50] for all studies assessing the association 
of the MAPT haplotypes and the risk of AD. From this list we selected all papers 
studying the association between the H1/H2 haplotype of the MAPT gene and AD 
in Caucasian populations. In our meta-analysis we used the original papers to de-
rive the risk for AD stratifying by APOE*4 carrier status. Four papers that did not 
provide information on APOE genotype were excluded [20, 51-53]. We excluded 
two more papers that did not study Caucasian populations [18, 54]. Finally, we used 
8 studies in our analysis [17, 19, 21-23, 25, 27, 55]. The meta-analysis was carried out 
using the Review Manager V 4.2 package [56].
Results
Basic characteristics of cases and controls are shown in Table 1. There were sig-
nificantly more females among the AD patients compared to controls (p=0.0002) 
and the average kinship coefficient was significantly higher in patient pairs than in 
control pairs (P<0.0001). Also, the APOE*4 frequency was significantly increased 
in cases p=0.0001.
Out of the total number of SNPs genotyped (n=43), six had a failure rate over 10%. 
The genotypes of the remaining SNPs were in Hardy-Weinberg equilibrium (p > 
0.05). The resulting 37 SNPs were located between the chromosomal positions 
40526680 bp (hCV2536908) and 42372240 bp (hCV2275279), based on contig NT 
010783.14, build 36.1 of NCBI SNP database http://www.ncbi.nlm.nih.gov/proj-
ects/SNP/. Out of the 37 SNPs included in the analyses, 22 were distributed in 
eight confirmed genes, 10 in putative genes and five were on intragenic segments 
(Table 2).
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The LD structure of all the SNPs in cases and controls is shown in Figure 1. The 
cases (Figure 1a) showed a small LD block 722kb upstream the MAPT gene. This 
block was not detected in the control sample (Figure 1b). These two SNPs are lo-
cated in the N-myristoyltransferase 1 (NMT1) gene. SNP hCV2536908 (rs7219596) 
is a synonymous C to T substitution at codon 163 and SNP hCV341577 (rs1053733) 
is a G to A substitution at the 3’ untranslated region of the NMT1 gene. The 
NMT1 protein is involved in protein myristoylation, proliferation, and apoptosis 
[57]. We compared the LD between cases and controls using the LD contrast test 
and found a statistically significant difference between the two groups (p=0.03) for 
this region. The patient group showed a larger LD block than controls spanning 
154kb between SNPs hCV2560317 to hCV2598655. However, the difference in 
the length of the block was not statistically significant (p=0.20). We also tested 
the extent of LD in the region of the MAPT gene (between SNPs hCV3202946 
and hCV11936104) and found no significant difference between cases and controls 
(p=0.70).
Linkage analysis of the microsatellite markers only, showed a positive LOD score 
of 1.35 for the MAPT region. After inclusion of the selected tagging SNPs (7), 
the LOD score between SNPs hCV341577 (722kb upstream the MAPT gene) and 
hCV2275279 dropped below –2, excluding linkage of AD to this region. LOD 
scores corresponding to the flanking microsatellite markers of the MAPT region 
were –1.78 for marker D17S798 and –2.27 for marker D17S1868 (Figure 2).
We did not find significant evidence for association with AD for any of the studied 
SNPs (all nominal p values > 0.05) in the single SNP analysis (Table 3). Using 
haplotype analysis with two SNPs sliding windows, we detected nominal p values 
< 0.05 for the hCV341577 - hCV9254243 haplotype (p= 0.02) and the hCV2032862 
- hCV2032865 haplotype (p= 0.01). The 3 SNPs sliding window analysis showed 
nominal p values < 0.05 for the hCV2536908 - hCV2554844 haplotype (first 6 
SNPs). These significant p-values did not sustain when adjusting for multiple test-
ing. No significant evidence for association was found for the MAPT gene itself 
or its transcript region (SNPs indicated in italics, Table 3). Also, when stratifying 
for APOE*4, the MAPT region was not associated to AD (data not shown). When 
testing the H1/H2 haplotype in our population, we found that the H1 haplotype 
frequencies were 83% for cases and 79% for controls (p=0.61). The frequencies for 
the Hlc haplotype were 31% in cases and 30% in controls (p=0.84).
Since we found nominal evidence for association 722 kb upstream of the MATP 
gene, which is 716 kb downstream from GRN, we sequenced all the exons and 
Chapter 2.2. The MAPT and GRN genes and AD
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splice sites of this gene in 17 patients ascertained from the GRIP program who 
were from families contributing to the LOD score. No mutations on the GRN gene 
were found in these patients.
Finally, we performed a meta analysis of the H1/H2 haplotypes by APOE*4. The 
studies are shown in Table 4. Overall, 12 studies have addressed the role of MAPT 
in AD. When analysing all studies, no significant association of the MAPT H1/H2 
haplotype and AD was found (OR=0.95, 95%CI 0.86-1.04, source: www.alzforum.
org) [50]. Our meta analysis showed that the frequency of the H2 haplotype in those 
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Table 4. Distribution of the MAPT HI and H2 haplotypes in the studies included 
in the meta analysis by APOE*4
TAU haplotypes-Number of Cases/Controls (%) 
Study Population Number Cases/Controls H1H1 H1H2 H2H2 H2 frequency
APOE*4+ 
Lilius, 1999 Sweden Clinical 130/19 100(15.2) /1 1(4.2) 28(8) / 8(7.8) 2(5.7) / 0(0) 12.3/21.1 
Lilius, 1999 Sweden Population based 44/46 31(4.7) / 34(13.1) 13(3.7) /11(10.7) 0(0) /I (4.5) 14.8/14.1 
Roks, 1999 Netherlands 66/38 36(5.5) / 26(10) 27(7.7) / 10(9.7) 3(8.6) / 2(9.1) 25.0/18.4 
Baker, 2000 Finland 82/32 67(10.2) / 26(10) 14(4) / 6(5.8) 1 (2.9) / 0(0) 9.8/9.4 
Bullido, 2000 Spain 103/31 50(7.6) /1 9(7.3) 47(13.4) / 6(5.8) 6(17. 1)/ 6(27.3) 28.6/29.0 
Kwon, 2000 USA Washington 141/68 92(14) / 46(17.8) 43(12.3) / 17(16.5) 6(17.1) / 5(22.7) 19.5/19.9 
Russ, 2001 United Kingdom 111/39 61(9.3) / 25(9.7) 47(1 3. 4) /1 0(9.7) 3(8.6) / 4(1 8.2) 23.9/23.1 
Peplonska, 2003 Poland 58/21 42(6.4) /1 5(5.8) 15(4.3) / 6(5. 8) 1 (2.9) / 0(0) 14.7/14.3 
Myers, 2005 USA+UK 236/65 131(19.9) / 40(15.4) 93(26.5) / 22(21.4) 12(34.3) / 3(13.6) 24.8/21.5 
Arias, 2006 Netherlands 72/25 47(7.2) /1 7(6.6) 24(6.8) / 7(6.8) 1(2.9) /I (4.5) 18.1/18.0 
Total 1043/384 657/259 351/103 35/22 20.2/19.1 
APOE*4- 
Lilius, 1999 Sweden Clinical 42/43 34(7.2) / 3 1(3. 8) 9(4.2) / 10(2.4) 2(8) / 2(3. 8) 14.4/16.3 
Lilius, 1999 Sweden Population based 50/130 38(8) / 87(10.5) 1 1(5.2) / 38(9 .2) 1 (4) / 5(9.6) 13.0/18.5 
Roks, 1999 Netherlands 35/78 25(5.3) / 44(5.3) 9(4.2) / 29(7) 1 (4) / 5(9.6) 15.7/25.0 
Baker, 2000 Finland 100/191 82(17.3) / 194(23.5) 1 8(8.5) / 28(6.8) 0(0) /I (1.9) 9.0/6.7 
Bullido, 2000 Spain 64/163 23(4.8) / 79(9.6) 36(17) / 75(18.2) 5(20) / 9(17.3) 35.9/28.5 
Kwon, 2000 USA Washington 125/210 83(17.5) / 132(16) 39(18.4) / 68(16.5) 3(12) / 10(19.2) 18.0/21.0 
Russ, 2001 United Kingdom 89/150 53(11. 2) / 79(9.6) 33(15.6) / 63(15.3) 3(12) / 8(15.4) 21.9/26.3 
Peplonska, 2003 Poland 42/79 34(7.2) / 59(7.1) 8(3.8) / 17(4.1) 0(0) / 3(5.8) 9.5/14.6 
Myers, 2005 USA+UK 118/187 77(16.2) / 101(12.2) 31(14.6) / 77(18.6) 10(40) / 7(13.5) 21.6/24.6 
Arias, 2006 Netherlands 44/30 26(5.5) / 20(2.4) 1 8(8.5) / 8(1. 9) 0(0) / 2(3. 8) 20.5/20.0 
Total 712/1261 475/826 212/413 25/52 18.4/20.5 
Chapter 2.2. The MAPT and GRN genes and AD
1
Fi
gu
re
 3
: W
ei
gh
te
d 
O
dd
s 
R
at
io
s 
an
d 
95
%
 c
on
fi
de
nc
e 
in
te
rv
al
s 
fo
r 
th
e 
ri
sk
 o
f 
A
D
 f
or
 c
ar
ri
er
s 
of
 t
he
 H
2 
h
ap
lo
ty
p
e 
of
 t
he
 M
A
P
T
 
ge
ne
, i
n
 A
P
O
E
*4
 c
ar
ri
er
s 
(a
b
ov
e)
 a
n
d 
no
n
-c
ar
ri
er
s 
(b
el
ow
).
A
P
O
E
*4
+
 
 
 
 
 
 
0
.
6
6
 
[
0
.
2
6
,
 
1
.
6
9
]
 
 
 
 
 
 
 
 
 
 
 
 
 
0
.
6
4
 
[
0
.
3
0
,
 
1
.
3
5
]
 
 
 
 
 
 
 
 
 
 
 
 
 
0
.
5
2
 
[
0
.
2
2
,
 
1
.
2
2
]
 
 
 
 
 
 
 
 
 
 
 
 
 
1
.
6
8
 
[
0
.
9
2
,
 
3
.
0
4
]
 
 
 
 
 
 
 
 
 C
as
e
 C
on
tr
ol
 O
R
 (f
ix
ed
)
 W
ei
gh
t
 O
R
 (f
ix
ed
)
 9
5%
 C
I
 %
 9
5%
 C
I
 L
ili
us
-S
w
ed
en
 C
lin
ic
 b
as
ed
 
 
 
 
 
 
 
1
1
/
5
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
2
/
4
3
 
 
 
 
 
 
 
 
 
 
5
.
1
6
 L
ili
us
-S
w
ed
en
 P
op
ul
at
io
n 
ba
se
d 
 
 
 
 
 
 
 
1
2
/
5
0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4
3
/
1
3
0
 
 
 
 
 
 
 
 
 
8
.
8
0
 R
ok
s 
   
   
   
   
   
 
 
 
 
 
 
1
0
/
3
5
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
4
/
7
8
 
 
 
 
 
 
 
 
 
 
7
.
2
9
 B
ul
lid
o 
   
   
   
   
 
 
 
 
 
 
4
1
/
6
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8
4
/
1
6
3
 
 
 
 
 
 
 
 
 
8
.
2
5
 K
w
on
   
   
   
   
   
 
 
 
 
 
 
 
4
2
/
1
2
5
 
 
 
 
 
 
 
 
 
 
 
 
 
7
8
/
2
1
0
 
 
 
 
 
 
 
 
1
8
.
7
3
 
 
 
 
 
0
.
8
6
 
[
0
.
5
4
,
 
1
.
3
6
]
 
 
 
 
 
 
 
 
 B
ak
er
   
   
 
 
 
 
 
 
1
8
/
1
0
0
 
 
 
 
 
 
 
 
 
 
 
 
 
2
3
/
1
9
1
 
 
 
 
 
 
 
 
 
6
.
2
8
 
 
 
 
 
1
.
6
0
 
[
0
.
8
2
,
 
3
.
1
4
]
 
 
 
 
 
 
 
 
 R
us
s 
   
   
   
   
   
 
 
 
 
 
 
3
6
/
8
9
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7
1
/
1
5
0
 
 
 
 
 
 
 
 
1
5
.
2
6
 
 
 
 
 
0
.
7
6
 
[
0
.
4
4
,
 
1
.
2
9
]
 
 
 
 
 
 
 
 
 P
ep
lo
ns
ka
   
   
   
  
 
 
 
 
 
 
 
8
/
4
2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
0
/
7
9
 
 
 
 
 
 
 
 
 
 
5
.
4
5
 
 
 
 
 
0
.
6
9
 
[
0
.
2
8
,
 
1
.
7
5
]
 
 
 
 
 
 
 
 
 M
ye
rs
   
   
   
   
   
 
 
 
 
 
 
4
1
/
1
1
8
 
 
 
 
 
 
 
 
 
 
 
 
 
8
4
/
1
8
5
 
 
 
 
 
 
 
 
2
0
.
6
9
 
 
 
 
 
0
.
6
4
 
[
0
.
4
0
,
 
1
.
0
3
]
 
 
 
 
 
 
 
 
 A
ri
as
   
   
   
 
 
 
 
 
 
 
1
8
/
4
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
2
/
3
0
 
 
 
 
 
 
 
 
 
 
4
.
0
9
 
 
 
 
 
1
.
0
4
 
[
0
.
4
0
,
 
2
.
6
7
]
 
 
 
 
 
 
 
 
7
2
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
2
5
9
 
 
 
 
 
0
.
8
6
 
[
0
.
7
0
,
 
1
.
0
5
]
 C
as
e
 C
on
tr
ol
 O
R
 (
fix
ed
)
 W
ei
gh
t
 O
R
 (f
ix
ed
)
 9
5%
 C
I
 %
 9
5%
 C
I
 L
ili
us
-S
w
ed
en
 C
lin
ic
 b
as
ed
 
 
 
 
 
 
3
0
/
1
3
0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8
/
1
9
 
 
 
 
 
 
 
 
9
.
7
6
 
 
 
 
 
0
.
4
1
 
[
0
.
1
5
,
 
1
.
1
2
]
 
 
 
 
 
 
 
 
 L
ili
us
-S
w
ed
en
 P
op
ul
at
io
n 
ba
se
d 
 
 
 
 
 
 
 
1
3
/
4
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
2
/
4
6
 
 
 
 
 
 
 
 
7
.
5
2
 
 
 
 
 
1
.
1
9
 
[
0
.
4
7
,
 
2
.
9
9
]
 
 
 
 
 
 
 
 
 R
ok
s 
   
   
   
   
   
 
 
 
 
 
 
3
0
/
6
6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
2
/
3
8
 
 
 
 
 
 
 
 
 
 
7
.
5
5
 
 
 
 
 
1
.
8
1
 
[
0
.
7
8
,
 
4
.
1
7
]
 
 
 
 
 
 
 
 
 B
ul
lid
o 
   
   
   
   
 
 
 
 
 
 
5
3
/
1
0
3
 
 
 
 
 
 
 
 
 
 
 
 
 
1
2
/
3
1
 
 
 
 
 
 
 
 
 
 
8
.
1
4
 
 
 
 
 
1
.
6
8
 
[
0
.
7
4
,
 
3
.
8
1
]
 
 
 
 
 
 
 
 
 K
w
on
   
   
   
   
   
 
 
 
 
 
 
 
4
9
/
1
4
1
 
 
 
 
 
 
 
 
 
 
 
 
 
2
2
/
6
8
 
 
 
 
 
 
 
 
 
1
7
.
6
1
 
 
 
 
 
1
.
1
1
 
[
0
.
6
0
,
 
2
.
0
6
]
 
 
 
 
 
 
 
 
 B
ak
er
  
 
 
 
 
 
 
1
5
/
8
2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
/
3
2
 
 
 
 
 
 
 
 
 
 
6
.
4
1
 
 
 
 
 
0
.
9
7
 
[
0
.
3
4
,
 
2
.
7
7
]
 
 
 
 
 
 
 
 
 R
us
s 
   
   
   
   
   
 
 
 
 
 
 
5
0
/
1
1
1
 
 
 
 
 
 
 
 
 
 
 
 
 
1
4
/
3
9
 
 
 
 
 
 
 
 
 
1
0
.
3
5
 
 
 
 
 
1
.
4
6
 
[
0
.
6
9
,
 
3
.
1
1
]
 
 
 
 
 
 
 
 
 P
ep
lo
ns
ka
   
   
   
  
 
 
 
 
 
 
1
6
/
5
8
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
/
2
1
 
 
 
 
 
 
 
 
 
 
5
.
8
0
 
 
 
 
 
0
.
9
5
 
[
0
.
3
1
,
 
2
.
8
8
]
 
 
 
 
 
 
 
 
 M
ye
rs
   
   
   
   
   
 
 
 
 
 
 
1
0
5
/
2
3
6
 
 
 
 
 
 
 
 
 
 
 
 
2
5
/
6
5
 
 
 
 
 
 
 
 
 
1
9
.
7
9
 
 
 
 
 
1
.
2
8
 
[
0
.
7
3
,
 
2
.
2
5
]
 
 
 
 
 
 
 
 
To
ta
l (
95
%
 C
I)
1
0
4
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
8
4
 
 
 
 
 
1
.
2
0
 
[
0
.
9
3
,
 
1
.
5
5
]
 0
.1
 0
.2
 0
.5
 1
 2
 5
 1
0
 A
ri
as
   
   
   
   
   
 
 
 
 
 
 
2
5
/
7
2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8
/
2
5
 
 
 
 
 
 
 
 
 
7
.
0
5
A
P
O
E
*4
- 
 Y
ea
r
19
99
19
99
19
99
20
00
20
00
20
00
20
01
20
03
20
05
20
06
 Y
ea
r
19
99
19
99
19
99
20
00
20
00
20
00
20
01
20
03
20
05
20
06
To
ta
l (
95
%
 C
I)
 0
.1
 0
.2
 0
.5
 1
 2
 5
 1
0
2
with APOE*4 was slightly increased in the patient group (p=0.11) (Table 4 above), 
resulting in an odds ratio of 1.20 (95% CI = 0.93-1.55) as shown in Figure 3. In 
the APOE*4 non-carriers (Table 4 below) the frequency of the H2 haplotype was 
higher in controls than in cases (p=0.23), resulting in an odds ratio of 0.86 (95% 
CI = 0.70-1.05). There was no significant evidence for interstudy heterogeneity in 
either of the groups (p=0.67 APOE*4 carriers, p=0.19 APOE*4 non-carriers).
Discussion
In our study including 37 SNPs we did not find evidence for association between 
AD and MAPT using single SNP and haplotype analysis. Moreover, linkage analy-
sis including 7 tagging SNPs in MAPT excluded linkage. In addition, our meta 
analysis, stratified by the APOE*4, did not yield significant evidence for associa-
tion between the H2 haplotype of MAPT and AD, making it unlikely that MAPT 
itself or in interaction with APOE is involved in the pathogenesis of AD. In the 
upstream region of the MAPT gene, several SNPs showed nominally significant 
evidence for association in the haplotype analyses (nominal p=0.01). The same 
was seen for the haplotype hCV2032862-hCV2032865 (nominal p = 0.01). SNPs 
hCV2536908 and hCV341577 are located 722 kb upstream from the MAPT gene 
within the NMT1 gene. This region showed more LD in cases than in controls. 
NMT1 is located 716 kb downstream from the GRN gene, which was recently 
associated with frontotemporal  dementia [28, 29]. We sequenced the GRN gene in 
17 AD patients from families suggesting linkage to this region but did not find any 
mutation. When adjusting our association analyses for multiple testing, none of the 
association of the haplotypes upstream of MAPT remained significant.
Previous studies, including one study on the MAPT H1 haplotype and two stud-
ies of newly identified SNPs, found evidence for interaction between MAPT 
polymorphisms and APOE*4 allele [17, 18, 25]. Our study showed no evidence of 
association with any of our SNPs when considering this interaction. An increase 
of risk of AD was found for carriers of the Hlc haplotype in those without the 
APOE*4 allele [27]. We were not able to replicate this finding in our study in the 
isolated population. In our meta analysis of 1755 patients and 1645 controls, a weak 
association in carriers of the H2 haplotype to AD was found in APOE*4 carriers 
but the odds ratio was non-significantly increased (OR = 1.20, 0.93-1.55, p=0.22) 
compared to H1/H1 carriers. Although one may argue that even this meta-analysis 
lacks statistical power to detect an odds ratio of 1.2, it is also important to realise 
that studies of interaction are susceptible to false positive and false negative find-
ings. The absence of an overall effect and the opposite trend observed in those with 
and without APOE*4 suggests the association in subgroups is most likely explained 
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by random fluctuation. 
There is no doubt that the tau protein plays a pivotal role in the development of 
Alzheimer’s disease [16, 58]. However, our series of patients from the isolated popu-
lation did not show evidence for association, nor linkage to AD. Our meta-analysis 
of all studies conducted to date also failed to show an effect of MAPT on AD. Our 
study describes some increase in linkage disequilibrium upstream of MAPT, which 
was not explained by GRN or MAPT mutations. The association did not sustain 
when adjusting for multiple testing. None of the SNPs studied in the region showed 
strong association to AD nor was there evidence for linkage to this region making 
the presence of an AD gene very unlikely.
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Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized 
by global cognitive decline. We conducted a genome screen in a family including 
9 affected individuals with AD using 420 markers. The data were analysed with 
parametric linkage analysis. The highest multipoint LOD scores were 1.15 for 
markers D1S450, D7S2465 and D19S571. The latter LOD score was most likely 
explained by the presence of APOE*4 in the patients. A two locus linkage analyses 
for the chromosomes 1 and 7 regions yielded a parametric LOD score of 2.92. 
The most promising candidate genes in the two regions are CASP9, TNFRSF1B 
and MTHFR on chromosome 1 and CDK5 and NOS3 on chromosome 7 which 
were selected for sequencing. No sequence variations were observed in the coding 
regions of the CASP9 and CDK5 genes but we found that allele A of the SNP 
rs9278 in the 3’UTR of the CDK5 gene was present in all affected individuals. 
The CDK5 gene may explain the linkage of AD to chromosome 7 in this family. 
However, we cannot exclude epistatic effects of this or other genes on chromosome 
7 with a gene on chromosome 1 or with APOE. 
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized 
by global cognitive decline involving memory, orientation, judgment, and reason-
ing [1]. Dominant mutations leading to the early onset form of AD are present in 
the Amyloid Precursor Protein (APP) gene [2-7], Presenilin 1 (PSEN-1) [3-7] and 
Presenilin 2 (PSEN-2) [8-10] genes. Although these genes play an important role in 
families affected with early onset AD, mutations are rare in the general population 
and explain a small number of cases [11, 12]. The e4 allele of APOE gene (APOE*4) 
has been associated with early and late onset AD [13, 14].
The major pathway involved in disease development is the amyloid beta cascade 
[15]. Aggregation of the Amyloid ß (Aß) protein is one of the key features of AD 
[16]. The second key pathway involved in AD pathology is the microtubule associ-
ated protein tau (MAPT) pathway [17]. In AD brains, the tau protein is hyperphos-
phorylated, truncated, and aggregated into neurofibrillary tangles (NFTs).
The genes identified to date explain less than 20% of all AD patients [12]. It has 
been proven difficult to identify new AD genes  [18]. In the past decade, various 
genes have been implicated in AD by either association or linkage. However, few of 
these findings have been confirmed. Up to September 2006, the AlzGene database 
(http://www.alzforum.org) has recorded 360 genes studied in Alzheimer’s disease 
[19]. Convincing evidence for linkage of AD has been reported on chromosomes 9, 
10, and 12 [20-27] but until now there is disagreement on the genes underlying the 
linkage results. The reason may be related to the fact that AD has a complex aetiol-
ogy. Moreover, the disease may be the consequence of interactions between genes, 
in particular in small families with multiple affected relatives in which the disease 
only clusters in 2 or 3 generations. This has been suggested for other complex 
disorders such as breast cancer [ 49].
There are still families segregating AD for which the gene responsible has not been 
localized. Given the strong clustering of this disease, a single or a limited number 
major genes are expected to explain the disease in these families. In this study we 
used a multilocus model to evaluate the evidence for epistatic effects in a single 
family segregating AD.
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Materials and Methods
Family Description
Family 3355 includes 31 relatives in three generations. We identified nine individu-
als with probable AD and were able to collect detailed clinical data on six of them. 
The clinical diagnosis of AD was based on clinical history, reviewing all medical 
records, neurological examination, neuropsychological tests, and neuroimaging 
data. Based on this information, a second physician verified the clinical diagnosis 
of the treating physician. Clinical diagnoses of AD were performed by a neurologist 
according to the NINCDS–ADRDA criteria [28]. The age at onset for the affected 
individuals ranged from 56 to 70 years with a mean at onset of 65 years. Blood 
samples were obtained for 24 individuals. All members of the family gave informed 
consent prior to participation and the medical ethics committee of the Erasmus 
MC approved this study. 
Genetic analyses
DNA was extracted using the phenol-chloroform isolation method. We performed 
a genome screen of AD in this family using 420 fluorescent microsatellite markers 
(Applied Biosystems linkage mapping set version 2, Foster City, CA). The APP, 
PSEN1, and PSEN2 genes were screened for mutations by direct sequencing. 
APOE genotyping was done using TaqMan allelic discrimination technology. The 
TaqMan assay utilized 5 nanograms of genomic DNA and 2 microliter reaction 
volumes. The amplification and extension protocol was as follows: an initial activa-
tion step of 10 min at 95 deg. preceded 40 cycles of denaturation at 95 deg. for 15 
s. and annealing and extension at 50 deg. for 60 s. Allele-specific fluorescence was 
then analyzed on an ABI Prism 7900HT Sequence Detection System with SDS v 
2.1 (Applied Biosystems, Foster City, CA).
Linkage Analyses
Parametric linkage analysis and haplotype reconstruction were done using SimWalk2 
v 2.91 [29-31]. Disease model was set to dominant; age dependent penetrances were 
computed based on population prevalence [32]. Disease allele frequency was set to 
0.01 and marker allele frequencies were estimated using all samples. APOE was 
included as a marker in the linkage analyses. Parametric two-locus linkage analysis 
was performed with GeneHunter–two locus parallel program (GHT) [33, 34]. 
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Disease model was set to dominant, with penetrance 0.99 and phenocopy rate 0.001. 
Because of the computational limitations of GHT, only the founders and affected 
persons of the second generation were used. Haplotypes of the two chromosomal 
regions for these individuals were transformed into genotypes as single markers, 
and used in the LOD score calculation by GHT.
Candidate gene selection by text mining
We developed a computational biology tool to prioritise AD candidate gene selec-
tion for sequence analysis. Our tool is based on the analysis of the Entrez-Genes 
database from the NCBI website (http://www.ncbi.nlm.nih.gov/). For each gene 
included in the Entrez-Genes database, the list of papers that is used as Gene 
References into Function (GeneRIF) is retrieved. The title, abstract, and MeSH 
headings of these papers are concatenated into one long text. This text is then 
indexed using the MeSH as well as the GO thesauri. Therefore, for each gene that 
contains reference literature in the database, a fingerprint pattern is constructed 
and stored in a database for future use [35]. A list of query concepts, in this case 
genes, needs to be input into the program. The query list selected was the list 
of genes described in the AD pathway included in the Kyoto Encyclopedia of 
Genes and Genomes (KEGG) database (http://www.genome.ad.jp/kegg/). The 
query genes were: A2M, LRP, LPL, APOE, APP, APBB1, APPBP1, BAC, GAPD, 
CASP3, PEN2, PSEN1, PSEN2, NCSTN, APH-1, IDE, MME, GSK3B, MAPT, 
CASP7 and SNCA [36, 37]. We matched our input list with all genes known in the 
NCBI database (http://www.ncbi.nlm.nih.gov/) using a matching algorithm based 
on a conceptual similarity score. Genes are then ranked on the conceptual similar-
ity score (between zero and one), which is assigned to each gene. This similarity 
score is basically a measurement of how concordant the fingerprint patterns of the 
genes in the NCBI database are compared to input list genes. The output is a list of 
genes ranked from the most to the less similar. From this output list, we then select 
candidate genes by the similarity score and their chromosomal location.
Mutation Screening
For mutation screening, the gene sequences were obtained from the UCSC database 
(http://genome.ucsc.edu/) assembly March 2006 [38, 39]. To facilitate amplification, 
the exons were divided in amplicons when the final sequenced product exceeded 
600 bp. A touchdown PCR was designed to amplify all the segments. PCR cycle 
conditions were: 7:30 min at 94°C; 10 cycles with 30 s denaturation at 94°C, 30 
s annealing temperatures ranging from 68°C to 59°C (-1°C per cycle) and 60 s 
extension at 72°C. Then 25 cycles with 30 s denaturation at 94°C, 30 s at 58°C 
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annealing temperature, and 60 s extension at 72°C. Final extension was set at 72°C 
for 5 min. Primers were designed using Primer3 software [40]. Direct sequenc-
ing of both strands was performed using Big Dye Terminator V 3.0 chemistry 
(Applied Biosystems). Fragments were loaded on an ABI 3100 automated sequencer 
and analyzed with DNA Sequencing Analysis V 3.7 and SeqScape V 2.5 packages 
(Applied Biosystems). Information on amplicons, primers, and size of fragments is 
available on request.
Results
Study Family
Figure 1 shows the pedigree of the study family and Table 1 shows the clinical 
characteristics of the patients. The numbers used in figure 1 refer to the same 
individuals in Table 1. Mean age at onset of disease was 65 years, ranging from 56 
to 70. All of the genotyped patients were APOE*4 carriers and seven out of nine 
patients were women. Mutations on APP, PSEN1, and PSEN2 were excluded by 
direct sequencing. In Figure 1 only the first two generations are shown, the third 
one is omitted for confidentiality of the participants.
Linkage Analyses
The parametric linkage analysis yielded 3 regions through out the whole genome 
with a LOD score greater than 1.0. Our analysis yielded a LOD score of 1.15 for 
marker D1S450, 1.15 for marker D7S2465 and 1.15 for marker D19S902. Haplotype 
analyses showed a ~17 cM shared region in chromosome 1 (including markers 
D1S450, D1S2667 and D1S2697), a ~25 cM shared region in chromosome 7 
(including markers D7S661, D7S798 and D7S2465), and a ~20 cM shared region 
in chromosome 19 (APOE, D19S902, D19S571 and D19S418). Since the APOE 
gene is included in this region, the linkage signal on chromosome 19 is most likely 
attributed to the effect of this gene. We next studied whether there is an epistatic 
effect of the loci on chromosomes 1 and 7. The two locus linkage analysis yielded 
a parametric LOD score of 2.92 for the combination of chromosomes 1 and 7. The 
co-segregation pattern of the haplotypes in the affected individuals of the first 
generation can be seen in Figure 2. Affected family members share all the chro-
mosomal regions, while the unaffected siblings miss some (9) or all co-segregating 
haplotypes (17 and 18). Individual 8 is not affected but shares the same haplotypes 
as the affected sibs.
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Candidate gene selection by concept profiling
There were 18913 genes with conceptual similarity scores ranging from 0 to 1. The 
distribution of the similarity indexes is plotted in figure 3. From this figure, we 
can see that 99.3% of the genes have a similarity index less than 0.25. Along with 
the increase of the similarity index, the number of genes decreased sharply and a 
plateau was encountered around 0.25. Therefore, we used this similarity score as a 
first stringent threshold for candidate gene selection. In the locus on chromosome 
1, we identified 112 genes in a 17cM region between markers D1S450 and D1S2697. 
123 genes were identified between markers D7S661 and D7S2465 in chromosome 
7. We ranked all these genes according to their similarity score and found that the 
genes in the locus of chromosome 1 with similarity scores above 0.25 were CASP9, 
TNFRSF1B and MTHFR. The genes on chromosome 7 with similarity scores 
above the threshold were CDK5 and NOS3. These genes have been previously 
associated with AD, [41-44] or apoptosis [45, 46].
Mutation Screening
Based on the results provided by the linkage analyses and the conceptual similarity 
scores, we selected the two top genes in the loci to perform mutation screening. 
We screened all the exons and plice sites of the CASP9 and CDK5 genes initially in 
four individuals of the study family. Individuals II-10, II-12, II-13, and, II-17 were 
initially selected due to the fact that they include the four haplotypes present in 
the family. No sequence variations were observed in the exons of the CASP9 and 
CDK5 genes but we found the Single Nucleotide Polymorphism (SNP) rs9278 in 
the 3’UTR of the CDK5 gene. This is a G>A substitution at 116 bp downstream 
from the stop codon in exon 12. Two of the affected individuals (II-10, II-12) se-
lected for initial sequencing were homozygotes for this SNP and the other one was 
heterozygote (II-13). The unaffected sib (II-17) was homozygote for the common 
variant G (figure 2). We later sequenced both genes in the other members of the 
family and confirmed the presence of allele A of the rs9278 SNP in all the affected 
individuals and also in individual II-8 who is unaffected. We did not detect any 
variations in the CASP9 gene in any of the family memebers screened.
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Discussion
In this study, we performed a whole genome scan in a family with 9 patients affected 
with AD. Three loci with LOD scores above 1.0 were found on chromosomes 1, 7 
and 19. All patients carry the APOE*4 allele which most likely explains the linkage 
to chromosome 19. A further two locus linkage analysis using only affected indi-
viduals yielded a LOD score of 2.92 for the combination of the loci of chromosomes 
1 and 7. The two locus model could only be studied using the first 2 generations 
due to computational limitations. It is expected that if all the unaffected persons in 
second generation are included in the analyses, the 2 locus LOD scores should be 
higher. We prioritised candidate gene selection using a computerized data mining 
strategy leading to CASP9 and CDK5 as the most promising candidate genes. The 
protein encoded by CASP9 is one of the proteins that activate Caspase 3, which is a 
key factor in the cleavage of Tau protein [46] and the Cdk5 protein is a key protein 
involved in Tau phosphorylation and AD [47, 48]. We did not find any mutation in 
the CASP9 or CDK5 coding exons but all patients shared the same allele of SNP 
rs9278 on the CDK5 gene. One individual who is unaffected carried the same 
haplotype. This may be the result of reduced penetrance of the gene responsible for 
AD in this family.
Five SNPs in the CDK5 gene were associated with early onset in two AD series 
and  we found that SNP rs9278 is a tagging SNP for a haplotype that is over 
presented in early-onset AD patients. In that, our findings corroborate with our 
earlier findings reported [44]. However, it is also possible that one of the 2 regions 
is a false positive finding. Of note is the fact that all patients carry the APOE*4 
allele suggesting that this gene may partly determine the presence of the disease in 
this family. The co-segregation of the chromosome 1 and 7 regions with AD may 
be also be explained by  a synergistic interaction between two genes involved in the 
aetiology of AD in this family. SNP rs9278 is located in 3’ UTR of the CDK5 gene. 
The functional role of this SNP is unknown and we could speculate that it could 
be in linkage disequilibrium with a functional polymorphism present elsewhere 
in the gene affecting, for example, exon splicing or mRNA stability. Alternatively, 
other genes may explain the linkage on chromosome 7. NOS3 is another obvious 
candidate gene for AD [42]. At chromosome 1, the TNFRSF1B and MTHFR genes 
are also candidates as they have been previously associated with AD [41, 43].
We developed a tool to select candidate genes for AD. CDK5 and CASP9 were 
identified as having the highest conceptual similarity scores followed by NOS3, 
TNFRSF1B and MTHFR. However, a limitation of this approach is that it makes 
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it impossible to identify those genes that are involved in unknown pathways of AD 
unless there are publications connecting the genes or proteins to those specified in 
the pathways.
In conclusion, our results suggest that the CDK5 gene may be implicated in AD 
in this family but we cannot exclude another locus. Our data are compatible with 
epistatic effects of genes on chromosome 1 and 7 which perhaps together with 
APOE*4 increase the risk of AD.
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Abstract
Although the role of the Cdk5 protein in Alzheimer’s disease (AD) is well recog-
nized, there have been relatively few studies investigating genetic variants in the 
CDK5 gene in AD. In this study we assessed the association between five previ-
ously described Single Nucleotide Polymorphisms (SNPs) in the CDK5 gene and 
AD by means of logistic regression and haplotype association analysis. Including 
all prevalent and incident AD cases, we found a significantly increased risk of AD 
for carriers of the GG genotype of SNP rs2069442 (OR=1.8, 95% CI 1.16-2.79, 
p=0.009) in those without APOE*4. When limiting the analysis to incident cases 
without APOE*4, carriers of the GG genotype showed a 2-fold increase of risk for 
AD (95%CI 1.28-3.12, p=0.02). Variations in the CDK5 gene can be described in 
5 haplotype blocks. In our analysis, the haplotype tagged by the G allele of SNP 
rs2069442, was significantly associated to AD (p=0.05). In conclusion, our study 
suggests that CDK5 may be associated to AD.
Chapter 3.1. Assoction between the CDK gene and AD
93
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by loss of 
neurons, cognitive impairment and dementia. The characteristic pathology of the 
brains of patients includes extracellular Amyloid ß (Aß) plaques aggregation and 
intracellular neurofibrillary tangles (NFTs) comprised of the hyperphosphorylated 
Tau protein.
There is growing evidence that cyclin-dependent kinase 5 (Cdk5) is a key protein 
involved in the pathogenesis of AD [1-3]. Cdk5 is composed of 293 amino acid resi-
dues and exhibits serine/threonine kinase activity [4, 5]. The interaction between 
Cdk5 and its regulatory subunits p35/p39 plays a key role in neuronal growth and 
migration processes [3]. Cdk5 is critical to synapse formation and synaptic plasticity, 
pivotal processes for learning and memory [6-8]. Deregulation of Cdk5 activity and 
calpain-mediated cleavage of p35 in to p25 has been observed in AD brains [9]. It 
was recently demonstrated that the prolonged expression of p25 results in impaired 
spatial learning, brain atrophy and hippocampus neuronal loss [10].
Cdk5 may also be involved in the abnormal phosphorylation of tau, contributing 
to the formation of NFTs [11] and may be a key protein linking NFTs and senile 
plaques [1, 9]. Cdk5 co-localizes with filamentous tau deposits and has increased 
activity in several tauopathies and AD [3, 12-14]. Deficiency in APP results in 
higher levels of tau phosphorylation and Cdk5 kinase activity [15]. Cdk5 is not 
only involved in hyperphosphorylation of tau, but also contributes to increased 
susceptibility to neuronal death.
Although the role of the Cdk5 protein in AD is well recognized, there have been 
relatively few studies investigating the role of genetic variants in the CDK5 gene in 
AD [16]. This gene is located in chromosome 7q36, is a 4089 bp long gene and in-
cludes 13 exons with only one transcript described (www.ensembl.org). Our group 
sequenced the CDK5 gene and its regulatory elements and studied five tagging 
Single Nucleotide Polymorphisms (SNPs) in a series of 85 early onset AD patients 
from Sweden and 104 early onset patients from The Netherlands [17]. These rela-
tively small series suggested an association between CDK5 and AD. The aim of 
this study is to assess the five previously described SNPs in the CDK5 gene in the 
Rotterdam Study, a population based follow up study in which 7983 individuals 
have been followed for 12 years [18].
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Materials and Methods
Patient ascertainment
The study is part of the Rotterdam Study, a Dutch population-based cohort study 
that investigates the occurrence and determinants of diseases in the elderly [18]. 
Baseline examinations, including a detailed questionnaire, physical examination, 
and blood collection, were conducted between 1990 and 1993. The medical ethics 
committee of Erasmus Medical Centre approved the study protocol.
The diagnosis of dementia was made following a stringent three-step protocol [19, 
20]. Briefly, all subjects were screened at follow-up visits (1997-1999, 1999-2000 
and 2000-2003) using two tests of cognition: the Mini-Mental State Examination 
(MMSE) [21] and Geriatric Mental State Schedule (GMS) [22]. Participants that 
were screen-positives (MMSE score < 26 or GMS organic level > 0) underwent 
the Cambridge examination for mental disorders of the elderly (CADMEX). A 
neuropsychologist examined subjects who were suspected of having dementia if 
additional neuropsychological testing was required for diagnosis. In addition, the 
total cohort was continuously monitored for incident dementia through a com-
puterized link between the study databases and digitalized medical records from 
general practitioners and the Regional Institute for Outpatient Mental Health Care 
until January 1, 2005. The diagnosis of dementia and subtypes of dementia was 
made in accordance with internationally accepted criteria for dementia (DSM-III-
R) [23] and Alzheimer disease (NINDS-ADRDA) [24] by a panel of a neurologist, 
neuropsychologist and research physician.
Genotyping
Genomic DNA was extracted from whole blood samples using standard methods 
[25]. The apolipoprotein E (APOE) gene was genotyped using the primer and 
amplification conditions described by Wenham et al. [26]. The SNPs in the CDK5 
gene selected to be analyzed in this study were previously described as tagging SNPs 
in this gene. [17]. The SNPs were selected after sequencing 70 familial Dutch early 
onset AD patients. We genotyped 318 samples twice for every SNP and used them 
as controls by comparing both genotypes, discordant genotypes were excluded. 
The percentage of concordant sample pairs tested was 100% for SNPs rs2069454, 
rs891507 and rs9278 and 99.7% (1 discordant sample) for SNPs rs2069442 and 
rs2069459. The general description of the SNPs selected for this study is shown in 
Table 1.
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Samples were genotyped with TaqMan allelic discrimination Assays-By-Design 
(Applied Biosystems, Foster City, CA).  Forward and reverse primer sequences 
were GGGCACACTGGGAACCA and GCGGAGGCAAACCTTGGA for SNP 
rs2069442, GAGCCGACCCGTTGCT and GAGAGGGAGAAGGGAGTCAGA 
for SNP rs2069454, CCTTGCTTTCCTCTGCCTTGA and 
ACTGCCCTCACCCATTGTG for SNP rs819507, CACCCTGCCCCTGAAGATG 
and CCACGGAGTCAAGGATCACTT for SNP rs2069459 and 
TGTGCTCCAGCAGTGCT and TCCACAAAGGGAGTGAGAAATTCG 
for SNP rs9278. The minor groove binding probes used were: 
TTCCTGGGACTTGAAG-VIC and CCTGGGAGTTGAAG-FAM for SNP 
rs2069442, CATGCAACTGTGCCC-VIC and ATGCAAGTGTGCCC-FAM for 
SNP rs2069454 (designed using the reverse strand), CAAAACTCCACGGACTC-
VIC and CAAAACTCCATGGACTC-FAM for SNP rs819507 (designed using the 
reverse strand), CAGCTGTGGCCCTT-VIC and CAGCTTTGGCCCTT-FAM 
for SNP rs2069459 and, CCACCCCGGCTGG-VIC and CCCACCCTGGCTGG-
FAM for SNP rs9278 (designed using the reverse strand). The assays utilized 5 
nanograms of genomic DNA and 2 microliter reaction volumes. The amplification 
and extension protocol was as follows: an initial activation step of 10 min at 95 deg. 
preceded 40 cycles of denaturation at 95 deg. for 15 s. and annealing and extension 
at 50 deg. for 60 s. Allele-specific fluorescence was then analyzed on an ABI Prism 
7900HT Sequence Detection System with SDS v 2.1 (Applied Biosystems, Foster 
City, CA).
Table 1. Description of the 5 CDK5 SNPs
*According to accession number NT007914.14 from NCBI (www.ncbi.nlm.nih.
gov/SNP/)
  


   
   
   
   
   
   
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Statistical Analysis
Hardy-Weinberg equilibrium (HWE) was assessed for all genotypes using the χ2 
statistic. Linkage disequilibrium (LD) pattern of the CDK5 SNPs was determined 
using HAPLOVIEW [27]. Also, genotype frequencies of the CDK5 SNPs were 
compared between cases and controls using the χ2 test. Odds ratios (ORs) and 
95% confidence intervals (CIs) were estimated using multivariate logistic regres-
sion adjusting for age, gender and the APOE*4 allele using all available AD cases 
(prevalent and incident). The APOE*4 stratified analyses were adjusted for age and 
gender. Haplotypes were estimated using the haplo.em function implemented in 
the haplo.stats package [28], which computes maximum likelihood estimates of 
haplotype probabilities. Posterior probabilities of haplotype pairs for each subject 
are also computed to account for the fact that there may be more than one pair of 
haplotypes that are consistent with the observed marker phenotypes. Haplotype 
association analyses were done using the haplo.score [29] function implemented 
in haplo.stats. Briefly, this package computes score statistics to test associations 
between haplotypes and a wide variety of traits, including binary, allowing for 
adjustment for other determinants.
Table 2. General characteristics of the study population
a 389 incident and 160 prevalent
* p < 0.01 = for cases vs. controls
  
  
  
  
  
  
  
  
  
  
  
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Results
General characteristics of the AD patients and non-affected individuals are shown 
in Table 2. Cases were significantly older than control subjects (p < 0.01). Also, 
there were significantly more women (p< 0.01) and APOE*4 carriers in the cases 
(p < 0.01). No deviations from Hardy-Weinberg Equilibrium were found for any of 
the CDK5 SNPs (p values ranging from 0.21 to 0.96). No differences were found 
in the proportion of successfully genotyped individuals between cases and controls 
for any of the CDK5 SNPs.
The distribution of the CDK5 SNPs in AD cases (prevalent and incident) and 
controls is shown in Table 3. Overall, there was no difference in the genotypic 
distribution of any of the SNPs between AD cases and controls. After stratifying 
by APOE*4, we found a statistically significant difference in the distribution of 
SNP rs2069442 between cases and controls in those without APOE*4 (χ2 = 9.68, 
p = 0.008). This association was explained by an increased frequency of the GG 
genotype in cases. After adjustment for age, gender and APOE*4, a significant 
trend was seen for SNP rs9278 in the overall group (pfor trend = 0.04) in which the 
frequency of the rare allele (A) was decreased in patients. No further differences in 
the genotypic distribution of any of the other CDK5 SNPs were seen overall or in 
the analysis stratified by APOE*4.
Table 4 shows the odds ratios overall and stratified by APOE*4 including all 
prevalent and incident cases. For SNP rs2069442 a non-significant increase in the 
odds ratio was seen in the overall analysis for the GG carriers compared to the CC 
carriers (OR = 1.33, 95% CI 0.92-1.93, p=0.11). In those without APOE*4, the OR 
increased to 1.8 (95% CI 1.16-2.71, p=0.009). When limiting the analysis to incident 
cases only, carriers of the GG genotype without the APOE*4 allele showed a 2-fold 
increase of risk for AD (95%CI 1.28-3.12, p=0.02). The difference in the relation-
ship of the CDK5 gene and AD between APOE*4 carriers and non-carriers was 
statistically significant (p for interaction = 0.05).
For SNP rs9278, which showed a significant trend, the odds ratios were 0.65 (95% 
CI 0.37-1.15) for the AA carriers and 0.84 (95% CI 0.68-1.04) for the GA carriers 
compared to GG carriers in the overall group (Table 4). 
Overall, the mean age at onset in patients carrying the GG genotype of SNP 
rs2069442 (89.65 years, SD = 8.44) did not differ significantly from that of the 
other patients (88.51 years, SD = 7.80 for CG carriers and 87.86 years, SD = 8.02 
for CC carriers, p=0.41). Also, when comparing the age at onset of those patients 
carrying the GG genotype of SNP rs2069442 to all other patients in those without 
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 Overall APOE*4+ APOE*4-
SNP Cases (%) Controls (%) Cases (%) Controls (%) Cases (%) Controls (%)
   
rs2069442   
   
CC 295 (54.6) 3119 (55.2) 126 (58.9) 827 (56.4) 159 (51.6) 2172 (55) 
CG 201 (37.2) 2169 (38.4) 79 (36.9) 541 (36.9) 115 (37.3) 1524 (38.6) 
GG 44 (8.1) 367 (6.5) 9 (4.2) 99 (6.7) * 34 (11.0) 254 (6.4) 
Total 540 5655 214 1467 308 3950 
   
rs2069454      
GG 489 (89.9) 5127 (90.4) 192 (89.7) 1334 (90.1) 282 (90.4) 3577 (90.4) 
GC 55 (10.1) 525 (9.3) 22 (10.3) 143 (9.7) 30 (9.6) 363 (9.2) 
CC 0 (0) 21 (0.4) 0 (0) 4 (0.3) 0 (0) 16 (0.4) 
Total 544 5673 214 1481 312 3956 
   
rs891507      
GG 397 (73.2) 3980 (70.6) 152 (71) 1060 (71.9) 231 (74.5) 2750 (70) 
GA 132 (24.4) 1512 (26.8) 55 (25.7) 366 (24.8) 73 (23.5) 1081 (27.5) 
AA 13 (2.4) 148 (2.6) 7 (3.3) 49 (3.3) 6 (1.9) 96 (2.4) 
Total 542 5640 214 1475 310 3927 
   
rs2069459      
GG 193 (35.5) 2222 (39.3) 71 (32.9) 573 (39) 120 (38.8) 1568 (39.8) 
GT 269 (49.5) 2635 (46.7) 112 (51.9) 670 (45.6) 145 (46.9) 1839 (46.7) 
TT 81 (14.9) 791 (14) 33 (15.3) 225 (15.3) 44 (14.2) 535 (13.6) 
Total 543 5648 216 1468 309 3942 
   
rs9278a      
GG 361 (67.4) 3526 (63.3) 140 (66.4) 919 (63.6) 206 (67.1) 2447 (62.9) 
GA 160 (29.9) 1804 (32.4) 67 (31.8) 465 (32.2) 90 (29.3) 1275 (32.8) 
AA 15 (2.8) 236 (4.2) 4 (1.9) 61 (4.2) 11 (3.6) 166 (4.3) 
Total 536 5566 211 1445 307 3888 
Table 3. Distribution of AD cases and controls by CDK5 SNPs overall and strati-
fied by APOE*4
* p = 0.008, a ptrend = 0.04
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Table 4. The relationship between CDK5 SNPs and AD in the Rotterdam Study
* OR is calculated for GC compared to GG as ref. ( NA = not applicable)
a Models adjusted for age, sex and APOE*4
† Models adjusted for age and sex
APOE*4, we found no significant differences (90.29 years, SD = 8.43 versus 88.13 
years, SD = 7.95).
There is strong LD between the SNPs (D’ values ranging from 0.96 to 1.00). 
Haplotype frequencies are shown in Table 5. Five haplotypes (Haplotype A 
– Haplotype E) comprised >98% of all observed variability and have been pre-
viously described [17]. The overall haplotype distributions were not significantly 
  † †
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
100
different between cases and controls. After stratification by APOE*4, we found an 
increase in frequency of haplotype C in cases in those without the APOE*4 allele 
(p = 0.05). Haplotype C is tagged by the G allele of SNP rs2069442, which is also 
over represented in the single SNP association analysis. We next examined the 
association between the CDK5 haplotypes with AD using the haplo.score function 
from haplo.stats [28] controlling for age sex and APOE*4. We did not see an asso-
ciation between any of the CDK5 haplotypes and AD in the overall analysis. After 
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stratification by APOE*4, we found a statistically significant association between 
haplotype C and the disease (p =0.05, Table 5). For haplotype B, tagging the A 
allele of SNP 9278, borderline association was found in the overall analysis (p = 
0.06).
 
Discussion
In this population-based study, we observed a 2-fold risk of AD for carriers of 
the GG genotype of the SNP rs2069442 of the CDK5 gene in non-carriers of the 
APOE*4 allele. Our haplotype analysis showed a statistically significant increase in 
frequency of haplotype C in AD cases, which is tagged by SNP rs2069442. SNP 
rs9278 showed a trend, which was explained by a reduced frequency of the rare al-
lele (A) in AD cases and the association was borderline significant in the haplotype 
analysis.
There have been few studies conducted on the relationship of the CDK5 gene with 
AD [16]. In our previous association study [17], focusing on early onset AD, we 
found SNP rs2069454 (which tags haplotype E) to be associated with the disease. 
In this study, we did not detect an effect of this specific haplotype with AD in our 
overall and stratified analyses. Although we cannot exclude spurious findings in 
either studies, the difference in the findings between them may also be explained 
by the age of onset of the patients.
We found a significant association between SNP rs2069442 and AD in the APOE*4 
non-carriers. This SNP is located in the regulatory region of the CDK5 gene mak-
ing the finding interesting for future functional studies. SNPs in the regulatory 
region are in particular of interest for late onset AD as mild effects may not lead to 
major pathology early in life but may result in later accumulating problems over age 
and ultimately leading to disease. 
Cdk5 is one of the key proteins involved in AD [30] and has been identified as 
a major candidate mediating tau hyperphosphorylation at specific protein sites 
characteristic for neurodegenerative tauopathies [31-34]. It has been suggested that 
Cdk5 can directly induce hyperphosphorylation of tau at disease-associated protein 
sites and that this may subsequently trigger neurofibrillary tangle formation in 
tauopathies [2, 14].
In order to become active, inactive monomeric Cdk5 needs to bind with its 
regulatory subunits p35 and p39, which are only expressed in the brain [3]. This 
neuron-specific expression of the Cdk5 protein complex is essential for neuronal 
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growth, development and migration. It has been previously demonstrated that Aß 
could provoke the conversion of the p35 and p39 subunits to p25 and p29 which 
are truncated proteins that nevertheless maintain the ability to bind with Cdk5 
activating it [11]. The aberrant activation of the Cdk5 protein by p25 is linked to 
neurodegeneration and the formation of neurofibrillary tangles [2].
In conclusion, our population-based study suggests that the CDK5 gene may be 
an independent risk factor for AD. We found an effect of SNP rs2069454 in the 
regulatory region of the CDK5 gene, suggesting that alterations in the expression 
of the protein may be relevant in neurodegenerative processes. The relation was 
most pronounced and significant in those without the APOE*4 allele, suggesting 
the effect is independent of the APOE gene. 
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Abstract
Similar to the apolipoprotein E (APOE) gene, the most common genetic determi-
nant for Alzheimer’s disease (AD), the cholesteryl ester transfer protein (CETP) is 
involved in lipid metabolism. We studied the I405V polymorphism of the CETP 
gene in relation to AD. We genotyped 525 AD cases and 5404 controls from the 
Rotterdam Study using a TaqMan allelic discrimination assay. Odds ratios (OR) for 
AD were estimated using logistic regression analysis. CETP VV carriers showed 
significantly increased HDL levels compared to the IV and II carriers. In the over-
all analysis of AD, the frequency of the VV carriers of the CETP polymorphism 
was non-significantly increased in patients OR = 1.33, 95% confidence interval 
0.96-1.90 p = 0.08. In those without the APOE*4 allele, the risk of AD for VV 
carriers was increased 1.67 fold (95% CI 1.11-2.52, p = 0.01). The difference in the 
relationship between CETP and AD between APOE*4 carriers and APOE*4 non-
carriers was statistically significant (p for interaction = 0.04). Our results suggest 
that the CETP gene increases the risk of AD in the absence of the APOE*4 allele, 
probably through cholesterol metabolism in the brain.
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Introduction
Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized 
by progressive memory loss and deterioration of cognitive function. Of the many 
genes studied thus far, the only consistently replicated genetic risk factor for AD 
has been the apolipoprotein E (APOE) gene. APOE, which transports cholesterol 
in the brain [1], may relate to AD by modifying the production of Amyloid β (Aβ). 
High cellular cholesterol may promote Aβ production and senile plaque deposition 
thus, increasing the risk of AD [2-7]. Cholesterol dysregulation is linked to the 
pathogenesis of AD [8, 9]. Lack of cholesterol supply to neurons impairs neuro-
transmission and synaptic plasticity [10] and induces neurodegeneration and tau 
pathology [11].  Also, there is some evidence that patients treated with cholesterol 
lowering drugs, such as statins, have a reduced prevalence of AD [12].
High Density Lipoprotein (HDL) is essential for the removal of excess cholesterol 
from cells exerting several potentially anti-atherogenic effects including reverse 
cholesterol transport from peripheral cells to the liver [13]. Cholesteryl ester trans-
fer protein (CETP) is a key player in lipid metabolism by catalysing the transfer of 
cholesteryl ester from HDL particles to triglyceride-rich lipoproteins in exchange 
for triglycerides [14]. CETP is a protein composed of 439 amino acid residues. It is 
coded by the CETP gene, which is located on chromosome 16q21 and has 14 exons. 
The 405V allele of the CETP I405V polymorphism in exon 14 has been associated 
with lower levels of CETP protein, higher levels of circulating HDL [15], a lower 
incidence of cardiovascular disease [15] and a longer survival [16].
Studies evaluating the role of the CETP gene in AD have shown contradictory 
results. While one previous study [17] showed evidence that the C-629A polymor-
phism of the CETP gene modifies the risk of AD in association with the APOE 
gene by reducing the risk of AD, another study found no effect of this gene on the 
disease [18]. We studied the I405V polymorphism of the CETP gene in relation to 
AD in a large population based study and investigated whether this polymorphism 
is independently associated with AD, or acts in concert with the APOE gene con-
ferring risk for the disease.
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Materials and Methods
Study Population
Our study is part of the Rotterdam Study, a population-based follow-up study of 
determinants of diseases in the elderly. All inhabitants of Ommoord, a suburb 
of Rotterdam, aged 55 years or over, were invited to participate. The design of 
the study has been previously described [19]. From all subjects, informed consent 
was obtained and the Medical Ethics committee of the Erasmus Medical Center 
approved the study. 7.983 participants (response rate of 78%) were examined at 
baseline (1990 to 1993). Information on age, smoking behavior and medical history 
was obtained using a computerized questionnaire. 
Patient ascertainment
Dementia was diagnosed following a three-step protocol [20, 21]. All participants 
were screened at follow-up visits using two tests of cognition: the Mini-Mental 
State Examination (MMSE) [22] and Geriatric Mental State Schedule (GMS) [23]. 
Participants that were screen-positives (MMSE score < 26 or GMS organic level 
> 0) underwent the Cambridge examination for mental disorders of the elderly 
(CADMEX). In addition, the cohort was continuously monitored for incident de-
mentia through computerized linkage between the study databases and medical 
records from general practitioners and the Regional Institute for Outpatient Mental 
Health Care until January 1, 2005. The diagnosis of dementia and subtype of de-
mentia was made in accordance with accepted criteria for dementia (DSM-III-R) 
[24] and Alzheimer disease (NINDS-ADRDA) [25] by a panel of a neurologist, 
neuropsychologist and a research physician.
Genotyping
DNA was extracted from whole blood samples using standard methods [26]. The 
APOE gene was genotyped using the conditions described by Wenham et al. [27]. 
Samples were genotyped for the CETP I405V polymorphism using TaqMan allelic 
discrimination Assays-By-Design (Applied Biosystems, Foster City, CA). We geno-
typed 317 samples twice and used them as controls by comparing both genotypes, 
and if present, samples with discordant genotypes were excluded.   Forward and 
reverse primer sequences are available on request. The assays utilized 5 nanograms 
of genomic DNA and 2 microliter reaction volumes. The amplification and exten-
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sion protocol was as follows: an initial activation step of 10 min at 95° C preceded 
40 cycles of denaturation at 95° C for 15 s. and annealing and extension at 50° C 
for 60 s. Allele-specific fluorescence was then analyzed on an ABI Prism 7900HT 
Sequence Detection System with SDS v 2.1 (Applied Biosystems, Foster City, CA).
Statistical Analysis
Genotype frequency of the CETP I405V was compared between cases and controls 
and Hardy-Weinberg equilibrium (HWE) were assessed for all genotypes using the 
χ2 test. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using 
multivariate logistic regression adjusting for age, gender and APOE*4 status using 
all available AD cases (prevalent and incident). The APOE*4 stratified analyses 
were adjusted for age and gender.  All  analyses  were  performed using SPSS 11.0.
Genotype II IV VV 
Total typed (%) 2949 (36.9) 2826 (35.4) 646 (10.1) 
Mean age of entry in years (SD) 69.4 (9.2) 69.5 (9.2) 69.1 (9.0) 
Female (%) 1702 (59.9) 1608 (59.1) 369 (59.0) 
Mean HDL levels mMol/L 
(SD)*
1.33 (0.37) 1.34 (0.36) 1.39 (0.39) 
Mean total cholesterol levels 
mMol/L  (SD) 
6.61 (1.21) 6.60 (1.24) 6.61 (1.23) 
APOE*4 carriers (%) 790 (29.3) 733 (28.2) 156 (26.8) 
Table 1. General characteristics of the study population stratified by CETP geno-
type
* p = 0.001
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Results
Table 1 shows the general characteristics of the study population. The distribution 
of the CETP I405V genotypes was in Hardy Weinberg Equilibrium (p= 0.38). The 
mean serum HDL level of the VV carriers was significantly increased compared to 
the IV and II carriers (p = 0.001). There were no statistically significant differences 
in the distribution of the other variables between the genotype groups.
The genotype frequencies of the CETP I405V polymorphism are shown in Table 
2. Overall, we did not find any significant difference in the genotypic distribution 
of the CETP I405V polymorphism between AD cases (prevalent and incident) and 
controls. After stratifying for APOE*4, we found a statistically significant differ-
ence in the distribution between cases and controls in those without APOE*4 (χ2 
= 6.62, p = 0.04).  This difference was explained by an increased frequency of the 
VV genotype in cases. 
Table 3 shows the odds ratios overall and stratified by APOE*4. Including all 
prevalent and incident cases, a non-significant increase in the odds ratios was seen 
in the  overall analysis  when comparing  the VV  carriers  to the II carriers of the
I405V polymorphism, (OR = 1.33, 95% CI 0.96-1.90, p = 0.08). In those without 
APOE*4, the OR increased to 1.67 (95% CI 1.11-2.52, p = 0.01). The IV carriers 
showed a non-significant increase in risk of AD compared to II carriers in those 
 Overall APOE*4+ APOE*4- 
Genotype Cases (%) Controls (%) Cases (%) Controls (%) Cases (%) Controls (%) 
    
    
II 236 (43.4) 2604 (46.1) 106 (49.8) 684 (46.7) 121 (38.8) 1806 (45.9) 
IV 249 (45.8) 2474 (43.8) 89 (41.8) 644 (43.9) 151 (48.4) 1738 (44.1) 
VV 59 (10.8) 566 (10.0) 18 (8.5) 138 (9.4) *40 (12.8) 394 (10.0) 
Total 544 5644 213 1466 312 3938 
* p = 0.04
Table 2. Distribution in cases and controls by CETP I405V polymorphism overall 
and stratified by APOE*4
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without APOE*4, OR = 1.26 (95% CI 0.96-1.64, p = 0.09). These estimates did 
not change after adjusting for serum HDL levels. Serum HDL level itself was not 
associated to AD. We did not detect an effect of the CETP gene on the risk of 
AD in those with APOE*4 (p VV carriers = 0.65) (Table 3). The difference in the 
relationship of the CETP gene and AD between APOE*4 carriers and non-carriers 
was statistically significant (p for interaction = 0.04). The mean age at onset in 
patients carrying the VV genotype of the CETP I405V polymorphism (88.64 years, 
SD = 7.19) did not differ significantly compared to that of the II and IV carriers 
(88.75 years, SD = 8.02 for IV carriers and 87.75 years, SD = 817 for II carriers, 
p=0.41). In those without the APOE*4 allele, the difference in age at onset between 
VV carriers and non-carriers was also not significant (p = 0.48).
Discussion
Our results suggest an increased risk of AD for the carriers of the VV genotype 
of the I405V polymorphism of the CETP gene. The increase in risk was 1.67-fold 
in non-carriers of the APOE*4 allele. No association was observed between this 
polymorphism of the CETP gene and AD in those with the APOE*4 allele. We 
detected a statistically significant difference in the relationship between CETP and 
AD in APOE*4 carriers and non-carriers (p for interaction = 0.04). The association 
was independent of serum HDL levels, which by itself, was not associated to AD.
The relationship of lipid transfer proteins as CETP and AD has been previously 
studied. In an experimental study, Yamada et al. showed that in brains of patients 
with AD, reactive astrocytes in grey and white matter exhibit CETP-like immu-
noreactivity. Thus, CETP-positive astrocytes may play a role in the pathology of 
Table 3. Association analyses between CETP I405V polymorphism and AD
¶ Models adjusted for age, sex and APOE*4, † Model adjusted for age and sex
   
   
   
   
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Alzheimer’s disease, in particular tissue repair [28]. Our findings partly overlap with 
those of other genetic studies. The CETP C-629A and the TaqI B polymorphisms 
have been studied in relation with AD. A study in a Spanish population of the 
relationship between these two polymorphisms and the APOE*4 allele indicated 
that the CETP gene modifies Alzheimer’s disease risk possibly through modulation 
of brain cholesterol metabolism [17]. On the other hand, the studies of Zhu et 
al., which evaluated the effect of two promoter and the TaqI B polymorphisms 
[18] and the study of Fidani et al, which also evaluated the effect of the TaqI B 
polymorphism found no effect of this gene on the disease [29].
Since the VV genotype is associated with lower levels of CETP and higher HDL, 
our study is compatible with the view that low CETP levels may increase the risk 
of AD through a reduction in neuronal repair capacity. An alternative mechanism 
is related to cholesterol removal by HDL, this is one of the mechanisms that the 
cell uses to keep the levels of cholesterol in their membranes fairly constant [9, 13, 
30], this would imply that VV carriers could be at lower risk of AD. The fact that 
we found this group (VV carriers) at a higher risk of AD could be explained by 
previous findings that suggest that the actions of the HDL in the transfer of lipids 
in brain may differ from these in the peripheral system [31]. In fact, the processing 
of cholesterol in brain is restricted in the central nervous system by the blood-
brain barrier, which is impermeable to plasma lipoproteins [32]. Unlike fatty acids 
that must be transported to the central nervous system from the periphery, brain 
cholesterol is mainly independent of dietary uptake or synthesis in the liver and is 
synthesized almost all in the brain [33].
Taken all together, our results suggest that the CETP gene increases the risk of AD 
independently of the APOE gene, probably through the regulation of cholesterol 
metabolism in the brain. However, our data are not supported by the literature. 
More studies are needed to clarify the role of the CETP gene as well as the CETP 
protein and HDL cholesterol in AD. 
Acknowledgements
Arias Vasquez is supported by a grant from the Centre of Medical Systems Biology, 
grant # 297-2003 and the hersenstichting Nederland. The Rotterdam Study is 
supported by the Erasmus Medical Center and Erasmus University Rotterdam, 
the Netherlands Organization for Scientific Research (NWO), the Netherlands 
Organization for Health Research and Development (ZonMw), the Research 
Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture 
and Science, the Ministry of Health, Welfare and Sports, the European Commission 
(DG XII), and the Municipality of Rotterdam.  The contributions of the general 
practitioners and pharmacists of the Ommoord district are greatly acknowledged.
Chapter 3.2. The CETP gene and the risk of AD
11
References
1. Mahley, R.W., K.H. Weisgraber, and Y. Huang, Apolipoprotein E4: A 
Causative Factor and Therapeutic Target in Neuropathology, Including Alzheimer’s 
Disease. Proc Natl Acad Sci U S A, 2006. 103(15): p. 5644-51.
2. Yanagisawa, K. and K. Matsuzaki, Cholesterol-Dependent Aggregation of 
Amyloid Beta-Protein. Ann N Y Acad Sci, 2002. 977: p. 384-6.
3. Yanagisawa, K., Cholesterol and Pathological Processes in Alzheimer’s 
Disease. J Neurosci Res, 2002. 70(3): p. 361-6.
4. Puglielli, L., R.E. Tanzi, and D.M. Kovacs, Alzheimer’s Disease: The 
Cholesterol Connection. Nat Neurosci, 2003. 6(4): p. 345-51.
5. Michikawa, M., The Role of Cholesterol in Pathogenesis of Alzheimer’s 
Disease: Dual Metabolic Interaction between Amyloid Beta-Protein and Cholesterol. 
Mol Neurobiol, 2003. 27(1): p. 1-12.
6. Michikawa, M., Neurodegenerative Disorders and Cholesterol. Curr 
Alzheimer Res, 2004. 1(4): p. 271-5.
7. Abad-Rodriguez, J., M.D. Ledesma, K. Craessaerts, S. Perga, M. Medina, 
A. Delacourte, et al., Neuronal Membrane Cholesterol Loss Enhances Amyloid 
Peptide Generation. J Cell Biol, 2004. 167(5): p. 953-60.
8. Wolozin, B., W. Kellman, P. Ruosseau, G.G. Celesia, and G. Siegel, 
Decreased Prevalence of Alzheimer Disease Associated with 3-Hydroxy-3-
Methyglutaryl Coenzyme a Reductase Inhibitors. Arch Neurol, 2000. 57(10): p. 
1439-43.
9. Simons, M., P. Keller, J. Dichgans, and J.B. Schulz, Cholesterol and 
Alzheimer’s Disease: Is There a Link? Neurology, 2001. 57(6): p. 1089-93.
10. Mauch, D.H., K. Nagler, S. Schumacher, C. Goritz, E.C. Muller, A. Otto, 
et al., Cns Synaptogenesis Promoted by Glia-Derived Cholesterol. Science, 2001. 
294(5545): p. 1354-7.
11. Fan, Q.W., W. Yu, T. Senda, K. Yanagisawa, and M. Michikawa, Cholesterol-
Dependent Modulation of Tau Phosphorylation in Cultured Neurons. J Neurochem, 
2001. 76(2): p. 391-400.
12. Reiss, A.B., Cholesterol and Apolipoprotein E in Alzheimer’s Disease. Am 
J Alzheimers Dis Other Demen, 2005. 20(2): p. 91-6.
13. Hersberger, M. and A. von Eckardstein, Modulation of High-Density 
Lipoprotein Cholesterol Metabolism and Reverse Cholesterol Transport. Handb 
Exp Pharmacol, 2005(170): p. 537-61.
14. Barter, P.J. and J.J. Kastelein, Targeting Cholesteryl Ester Transfer Protein 
for the Prevention and Management of Cardiovascular Disease. J Am Coll Cardiol, 
2006. 47(3): p. 492-9.
15. Blankenberg, S., H.J. Rupprecht, C. Bickel, X.C. Jiang, O. Poirier, K.J. 
Lackner, et al., Common Genetic Variation of the Cholesteryl Ester Transfer Protein 
11
Gene Strongly Predicts Future Cardiovascular Death in Patients with Coronary 
Artery Disease, in J Am Coll Cardiol. 2003. p. 1983-9.
16. Atzmon, G., M. Rincon, P. Rabizadeh, and N. Barzilai, Biological Evidence 
for Inheritance of Exceptional Longevity, in Mech Ageing Dev. 2005. p. 341-5.
17. Rodriguez, E., I. Mateo, J. Infante, J. Llorca, J. Berciano, and O. Combarros, 
Cholesteryl Ester Transfer Protein (Cetp) Polymorphism Modifies the Alzheimer’s 
Disease Risk Associated with Apoe Epsilon4 Allele. J Neurol, 2006. 253(2): p. 181-
5.
18. Zhu, H., R.K. Gopalraj, J.F. Kelly, D.A. Bennett, and S. Estus, Lack of 
Genetic Association of Cholesteryl Ester Transfer Protein Polymorphisms with 
Late Onset Alzheimers Disease. Neurosci Lett, 2005. 381(1-2): p. 36-41.
19. Hofman, A., D.E. Grobbee, P.T. de Jong, and F.A. van den Ouweland, 
Determinants of Disease and Disability in the Elderly: The Rotterdam Elderly 
Study. Eur J Epidemiol, 1991. 7(4): p. 403-22.
20. Vermeer, S.E., N.D. Prins, T. den Heijer, A. Hofman, P.J. Koudstaal, 
and M.M. Breteler, Silent Brain Infarcts and the Risk of Dementia and Cognitive 
Decline. N Engl J Med, 2003. 348(13): p. 1215-22.
21. Barendregt, J.J. and A. Ott, Consistency of Epidemiologic Estimates. Eur 
J Epidemiol, 2005. 20(10): p. 827-32.
22. Folstein, M.F., S.E. Folstein, and P.R. McHugh, “Mini-Mental State”. A 
Practical Method for Grading the Cognitive State of Patients for the Clinician. J 
Psychiatr Res, 1975. 12(3): p. 189-98.
23. Copeland, J.R., M.J. Kelleher, J.M. Kellett, A.J. Gourlay, B.J. Gurland, 
J.L. Fleiss, et al., A Semi-Structured Clinical Interview for the Assessment of 
Diagnosis and Mental State in the Elderly: The Geriatric Mental State Schedule. I. 
Development and Reliability. Psychol Med, 1976. 6(3): p. 439-49.
24. Associtaion, A.P., Diagnostic and Statistical Manual of Mental Disorders. 
1987.
25. McKhann, G., D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. 
Stadlan, Clinical Diagnosis of Alzheimer’s Disease: Report of the Nincds-Adrda 
Work Group under the Auspices of Department of Health and Human Services 
Task Force on Alzheimer’s Disease. Neurology, 1984. 34(7): p. 939-44.
26. Miller, S.A., D.D. Dykes, and H.F. Polesky, A Simple Salting out Procedure 
for Extracting DNA from Human Nucleated Cells. Nucleic Acids Res, 1988. 16(3): 
p. 1215.
27. Wenham, P.R., W.H. Price, and G. Blandell, Apolipoprotein E Genotyping 
by One-Stage Pcr. Lancet, 1991. 337(8750): p. 1158-9.
28. Yamada, T., M. Kawata, H. Arai, M. Fukasawa, K. Inoue, and T. Sato, 
Astroglial Localization of Cholesteryl Ester Transfer Protein in Normal and 
Alzheimer’s Disease Brain Tissues. Acta Neuropathol (Berl), 1995. 90(6): p. 633-6.
29. Fidani, L., A. Goulas, R. Crook, R.C. Petersen, E. Tangalos, A. Kotsis, 
et al., An Association Study of the Cholesteryl Ester Transfer Protein Taqi B 
Chapter 3.2. The CETP gene and the risk of AD
11
Polymorphism with Late Onset Alzheimer’s Disease. Neurosci Lett, 2004. 357(2): 
p. 152-4.
30. Jiang, X.C. and H.W. Zhou, Plasma Lipid Transfer Proteins. Curr Opin 
Lipidol, 2006. 17(3): p. 302-8.
31. Bjorkhem, I. and S. Meaney, Brain Cholesterol: Long Secret Life Behind a 
Barrier. Arterioscler Thromb Vasc Biol, 2004. 24(5): p. 806-15.
32. Vance, J.E., H. Hayashi, and B. Karten, Cholesterol Homeostasis in 
Neurons and Glial Cells. Semin Cell Dev Biol, 2005. 16(2): p. 193-212.
33. Jurevics, H. and P. Morell, Cholesterol for Synthesis of Myelin Is Made 
Locally, Not Imported into Brain. J Neurochem, 1995. 64(2): p. 895-901.

Chapter 3.3
Relationship of the 
ubiquilin 1 gene 
with Alzheimer’s and 
Parkinson’s disease and 
cognitive function
120
Abstract
Ubiquilin 1 (UBQLN1) is involved in the ubiquitination machinery, which has been 
implicated in Alzheimer’s disease (AD) as well as Parkinson’s disease (PD).  The 
gene encoding for UBQLN1 has been previously associated with AD. We studied 
the role of the SNP rs12344615 on the UBQLN 1 gene in AD, PD and cognitive 
function in a population based study, the Rotterdam Study, and a family based 
study embedded in the Genetic Research in Isolated Population (GRIP) program. 
The Rotterdam study includes 549 patients with AD and 157 patients with PD. 
The GRIP program includes a series of 123 patients with AD and a study of 1049 
persons who are characterized for cognitive function. Data were analysed using 
logistic and multiple regression analysis. We found no significant difference in risk 
of AD or PD by the UBQLN1 SNP 12344615 in our overall and stratified analyses 
in the Rotterdam Study. In our family based study, we did not find evidence for 
linkage of AD to the region including the UBQLN1 gene. In the family-based we 
also failed to detect an effect of this polymorphism on cognitive function. Our 
results suggest that it is unlikely that the SNP 12344615 of the UBQLN1 gene is 
related to the onset of AD, PD or cognitive function.
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Introduction
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most common 
neurodegenerative disorders in western societies. Familial aggregation of these two 
disorders has been observed suggesting a common genetic cause [1-3]. The ubiq-
uilin1 gene (UBQLN1, GeneID 29979) may be involved in both diseases. A single 
intronic Single Nucleotide Polymorphism (SNP) located downstream of exon 8 
(rs12344615) of the UBQLN1 gene has been associated with AD [4]. UBQLN1 is 
a 48075 bp gene that includes 11 exons and for which two transcripts have been 
described (www.ncbi.nlm.nih.gov).
UBQLN1 specifically interacts with presenilin 1 and 2 apparently increasing the level 
of these proteins [5], making the gene encoding for UBQLN1, which is located in 
a region showing linkage to AD, an interesting candidate for AD. UBQLN1 is also 
involved in the ubiquitination machinery, related with general protein degradation 
[6]. There is substantial evidence for disturbances in the ubiquitinization machinery 
in PD. This makes the UBQLN1 gene also of interest for PD [7]. Previous studies 
on the relationship of this gene and AD have shown contradicting results. While 
some studies found an association with AD or related quantitative traits for SNP 
rs12344615 [8, 9], other studies did not find any evidence for association [10-13]. 
No studies have been performed so far evaluating the relationship between the 
UBQLN1 gene and PD. We studied the role of the rs12344615 polymorphism in 
the UBQLN 1 gene in AD, PD and cognitive function in population and family 
based studies. 
Materials and Methods
Study populations
Rotterdam Study
This is a population-based follow-up study of determinants of diseases in the el-
derly. The design of the study has been previously described [14]. From all subjects, 
informed consent was obtained and the Medical Ethics committee of the Erasmus 
Medical Center approved the study. The diagnosis of dementia was made following 
a three-step protocol [15, 16]. Briefly, all subjects were screened during follow-up 
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visits (1997-1999, 1999-2000 and 2000-2003) with two tests of cognition (Mini-
Mental State Examination (MMSE) [17] and Geriatric Mental State Schedule (GMS) 
[18]). Screen-positives (MMSE score < 26 or GMS organic level > 0) underwent the 
Cambridge examination for mental disorders of the elderly (Camdex). A neuropsy-
chologist examined persons who were suspected of having dementia if additional 
neuropsychological testing was required for diagnosis. The diagnosis of dementia 
and subtypes of dementia was made in accordance with internationally accepted 
criteria for dementia (DSM-III-R) [19] and Alzheimer disease (NINCDS-ADRDA) 
[20] by a panel of a neurologist, neuropsychologist, and a research physician.
We also used a two-step design to identify subjects with PD [21]. Participants 
were screened for parkinsonian signs (resting tremor, rigidity, bradykinesia, or 
impaired postural reflexes) in a standardized way. Individuals who screened posi-
tive received a diagnostic workup including the Unified Parkinson’s Disease Rating 
Scale (UPDRS) [22] and neurological examination. In addition, the cohort was 
continuously monitored through computerized linkage to general practitioners’ 
medical files. PD was diagnosed if two or more parkinsonian signs were present 
in a person not taking antiparkinsonian drugs, or if at least one sign had improved 
after  medication  was  started, and  when  all  causes  of  secondary parkinsonism
Table 1. General characteristics of the Rotterdam study population stratified by 
SNP rs12344615 genotype
Parkinsonism cases include all PD cases
a 389 incident and 160 prevalent
b 89 incident and 68 prevalent
   
   
   
   
   
   
   
   
Chapter 3.3. The UBQLN1  gene and AD, PD and cognitive function
123
(dementia, use of neuroleptics, cerebrovascular disease, multiple system atrophy, or 
progressive supranuclear palsy) could be excluded [23].
Genetic Research on Isolated Populations (GRIP) study
The GRIP study is a family based study that aims to identify genes involved in 
complex diseases by selecting affected individuals and their relatives. The popu-
lation in which the study was conducted is a genetically isolated community in 
the Southwest of The Netherlands [24, 25]. The Medical Ethics Committee of 
the Erasmus Medical Center approved this study. The patient ascertainment was 
described previously [2]. Briefly, all AD patients (n = 123) were examined by one of 
two research physicians to re-evaluate the previous clinical diagnosis. Examination 
consisted of neurological examination and brief neuropsychological testing. A 
standard interview was performed with close relatives concerning symptoms, 
disease course, medical, social and family history [2]. Dementia was classified using 
the Clinical Dementia Rating Scale (CDR). We also reviewed all available medical 
records, neuropsychological test results and neuroimages to establish a diagnosis 
according to the NINCDS–ADRDA criteria [20].
Erasmus Rucphen Family (ERF) study
This is a family-based study of a recent genetically isolated population embeded in 
the GRIP study. The ERF study aims to identify susceptibility genes for complex 
disorders by studying quantitative traits. Its participants are all the descendants of 
22 families that had at least 5 children baptized in the community church between 
1850 and 1900. All living descendants of these families and their spouses, aged 
18 and older were invited to participate [24]. The Medical Ethics Committee of 
Erasmus Medical Center approved the study.
A battery of neuropsychological tests was administered to the ERF participants 
[24]. Five neuropsychological tests adapted to the Dutch language were used to 
evaluate different cognitive domains related to neurodegenerative disorders [26-
28], namely: the Dutch version of the auditory verbal learning test (AVLT) [29, 
30], the Trail Making Test (TMT) [31], the Stroop Color-word Test [32, 33], the 
verbal fluency test [34, 35], and the Block Design subtest of the Wechsler Adult 
Intelligence Test (WAIS) [36]. Individuals with a previous diagnosis of neurological 
or psychiatric disorders were excluded (n= 47). A more detailed description of these 
cognitive tests is included in our previous report [24].
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Genotyping
Genomic DNA was extracted from whole blood samples using standard methods 
[37]. All samples were genotyped with TaqMan allelic discrimination Assays-By-
Design (Applied Biosystems, Foster City, CA). Primer sequences are available on 
request. The amplification and extension protocol was as follows:  an initial activa-
tion step of 10 min at 95°C preceded 40 cycles of denaturation at 95°C for 15s 
and annealing and extension at 50°C for 60s. Allele-specific fluorescence was then 
analysed on an ABI Prism 7900HT Sequence Detection System with SDS v 2.1 
(Applied Biosystems, Foster City, CA). We genotyped 318 samples twice for SNP 
rs12344615 and used them as controls by comparing both genotypes, discordant 
genotypes were excluded. The percentage of concordant sample pairs tested was 
100%.
All samples from the GRIP study were genotyped using 18 flourescently labelled 
microsatellite markers from chromosome 9 which were, on average, 10 centim-
organs apart. The genotyping experiments were done following manufacturer 
instructions (Applied Biosystems, Foster City, CA).
For the Rotterdam study, the APOE gene was amplified using the primer and 
amplification conditions described by Wenham et al. [38]. For the GRIP and ERF 
studies, samples were genotyped for the APOE polymorphisms with TaqMan al-
lelic discrimination Assay-By-Design (Applied Biosystems, Foster City, CA). Primer 
sequences are available on request. The assays utilized 5 nanograms of genomic 
DNA and 2 microliter reaction volumes. Given the characteristics of the chemistry 
used for designing the TaqMan primers and probes, PCR conditions and analysis 
methods were the same used for the rs12344615 SNP.
Statistical analyses
Hardy-Weinberg equilibrium (HWE) for all genotypes and genotype frequencies 
of the rs12344615 polymorphism were compared between cases and controls using 
the χ2 test. For the patients of the Rotterdam Study, odds ratios (ORs) and 95% 
confidence intervals (CIs) were estimated using multivariate logistic regression 
adjusting for age, gender and APOE*4 using the SNP rs12344615 TT genotype as 
reference. We assessed the effect of the rs12344615 SNP on the age at onset of AD 
and PD using incident cases only using multiple regression analysis. All analyses 
were performed with SPSS 11.0 for windows package.
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For the GRIP study the Quasi-Likelihood Score (QLS) test of the CC-QLS pack-
age [39], was used for the association analysis to correct for familial relationships. 
For the CC-QLS test, kinship and inbreeding coefficients were calculated using our 
genealogy database. For those individuals whose genealogy was not available, the 
average kinship and inbreeding coefficients were used. Parametric linkage analysis 
for AD was performed using a dominant model. Age dependent penetrance was 
estimated on population prevalence [40]. The disease gene frequency was set to one 
percent. Allelic frequencies for microsatellite markers were estimated from unre-
lated controls. Linkage analysis was conducted using SimWalk2 V.2.91 [41-43].
We evaluated the association between SNP rs12344615 and cognitive function [24]. 
Given the skewed distributions of the AVLT-Trial VII, TMT-A, TMT-B, cards I, 
II and III of the Stroop colour-word and Block design tests, the data were log-
transformed to achieve normality. Data were analysed using the linear mixed model 
implemented in the SOLAR package [44]. The models were adjusted for age, age2, 
sex, inbreeding and general cognitive ability.
Overall APOE*4+ APOE*4 - 
Cases (%) Controls (%) Cases (%) Controls (%) Cases (%) Controls (%)
      
AD       
rs12344615       
TT 353 (64.3) 3789 (66.1) 137 (63.1) 1019 (68.1) 209 (66.8) 2615 (65.6) 
TC 178 (32.4) 1745 (30.5) 75 (34.6) 424 (28.3) 91 (29.1) 1241 (31.1) 
CC 18 (3.3) 194 (3.4) 5 (2.3) 54 (3.6) 13 (4.2) 133 (3.3) 
Total 549 5728 217 1497 313 3989 
       
PD       
rs12344615
TT 105 (66.9) 4035 (66.0) 33 (78.6) 1123 (67.2) 68 (63.6) 2754 (65.7) 
TC 45 (28.7) 1877 (30.7) 7 (16.7) 492 (29.4) 34 (31.8) 1297 (30.9) 
CC 7 (4.5) 205 (3.4) 2 (4.8) 57 (3.4) 5 (4.7) 141 (3.4) 
Total 157 6117 42 1672 107 4192 
       
Table 2. Distribution of Alzheimer’s and Parkinson disease cases and controls by 
SNP rs12344615 in the Rotterdam Study stratified by APOE*4
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Results
Rotterdam Study
The general description of the participants of the Rotterdam Study stratified 
by rs12344615 genotype is shown in table 1. The distributions of the genotype 
frequencies were in Hardy Weinberg equilibrium (p = 0.70). No significant differ-
ences between the genotype groups were found in mean age at entry, gender, or 
APOE*4 distribution. The total number of affected individuals with AD, PD or 
Parkinsonism was not significantly increased in carriers of the C allele, although the 
number of PD patients tended to be increased in those homozygous for this allele.
The distribution of rs12344615 in AD and PD cases and controls, overall and 
stratified by APOE*4, is shown in Table 2. We did not find a statistically significant 
difference in the distribution of this SNP between patients and controls. There was 
a modest non-significant increase in the frequency of CC genotype in AD patients 
in those without APOE*4 allele. We also found a non-significant increase in CC 
carrier frequency in the PD cases both with and without APOE*4 (Table 2).
We assessed the association between the rs12344615 polymorphism and the risk 
of AD and PD by means of logistic regression adjusting for age, sex and APOE*4 
(Table 3). There was a non-significant increase in risk of AD and PD for CC carriers 
of SNP rs12344615 in those without APOE*4 in the additive and recessive models. 
The difference in the relationship of the UBQLN1 gene and AD and PD between 
APOE*4 carriers and non-carriers was not statistically significant (p for interaction 
= 0.97 for AD and p for interaction = 0.83 for PD).
We tested the effect of SNP rs12344615 on age at onset of AD and PD patients. 
Overall, the mean onset of AD in patients carrying the rs12344615 CC genotype 
(86.59 years, SD = 8.88) was 2.8 lower than that of CT carriers (89.40 years, SD = 
8.76) and 1.2 years lower for TT carriers (87.80 years, SD = 7.50 for TT carriers) 
but this difference was not statistically significant (p = 0.14). When comparing the 
onset of PD patients carrying the CC genotype of SNP rs12344615 to all other PD 
patients we found no significant differences between the groups (CC genotype 
carriers= 86.59 years, SD = 8.88 versus other genotype carriers = 88.32 years, SD 
= 7.96).
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GRIP study
In this population there are more females in the AD cases compared to controls 
(p=0.0002) and the average kinship coefficient is higher in case pairs than in 
control pairs (P<0.0001). The APOE*4 frequency was significantly increased in 
cases compared to controls (p=0.0001) and the mean onset of AD was 74.8 ± 5.3 
years. There was no significant difference in the onset of AD between the genotype 
groups (74.01 years, SD = 4.97 for CC carriers, 74.84, SD = 4.97 for TC carriers and 
74.83, SD = 5.47 for TT carriers, p = 0.33).
There was some evidence for association between AD and marker D9S164 (nomi-
nal p = 0.04 without adjustment for multiple testing). Also, marker D9S285 showed 
a borderline nominally significant p value (nominal p = 0.07).
a OR estimated using the TT genotype carriers as reference group
b OR estimated using the TT/TC genotype carriers as reference group
¶ Models adjusted for age, sex, and APOE*4, † Models adjusted for age and sex
Table 3. Association analyses of SNP rs12344615 with Alzheimer’s and Parkinson’s 
disease in the Rotterdam Study
   
   
   
   
   
   
   
   
   
   
   
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SNP rs12344615 itself showed no association with AD in this population (nominal 
p = 0.74) (Table 4). Stratified analysis by APOE*4 showed no association between 
the tested markers and AD (data not shown). Linkage analysis for AD using the 
microsatellite markers and SNP rs12344615 yielded negative LOD scores. For SNP 
rs12344615,  the  LOD  score was below –2.0, excluding  linkage and LOD scores
Marker Position Cases (n=123) Controls (n=58) QLS P 
D9S288 9.83 121 57 9.90 0.54 
D9S286 18.06 121 56 5.64 0.93 
D9S285 29.52 119 57 17.39 0.07 
D9S157 32.24 119 51 8.47 0.29 
D9S171 42.73 118 56 10.76 0.22 
D9S161 51.81 120 54 5.63 0.69 
D9S273 65.79 114 54 2.92 0.97 
D9S175 70.33 117 56 18.75 0.13 
D9S167 83.41 113 57 18.23 0.20 
rs12344615 85.21a 120 58 0.11 0.74 
D9S283 94.85 121 55 13.89 0.31 
D9S287 103.42 115 57 7.33 0.50 
D9S1690 106.63 120 54 6.45 0.49 
D9S1677 117.37 116 56 11.49 0.40 
D9S1776 123.33 121 56 4.46 0.88 
D9S1682 132.09 120 54 5.31 0.38 
D9S290 140.86 121 57 7.96 0.34 
D9S164 147.91 121 54 18.87 0.04
D9S1826 159.61 120 57 4.04 0.78 
Position: position in centimorgans of each marker (according to NCBI build 36.1), 
p: nominal p values from CC-QLS test, Italic marker name: UBQLN1 rs12344615 
SNP, a genetic position estimated using physical position, Bold P indicate nominally 
significant CC-QLS p values
Table 4. Comparison of microsatellite markers and SNP rs12344615 allele frequen-
cies between AD cases and controls using CC-QLS on the GRIP population
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Values are regression coefficients (se) of the SNP rs12344615 on cognitive tests
Models adjusted for age age2, sex, inbreeding education, and general cognitive abil-
ity, † Log-transformed variables, a Positive effects correlate with worse cognitive 
performance, b WAIS III
Table . Effects of SNP rs12344615 of the ubiquilin1 gene on cognitive tests on 
the ERF population
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
130
corresponding to the microsatellite markers flanking the SNP rs12344615 ranged 
from –3.6 for marker D9S167 to –2.5 for marker D9S283.
ERF study
In the ERF study, for 1049 individuals, phenotypic and genotypic information was 
available. The frequencies of SNP rs12344615 genotypes were 54% for the TT 
genotype, 38% for the TC genotype and 8% for the CC genotype. These genotypes 
were in Hardy-Weinberg equilibrium (p = 0.18). There was no significant difference 
in the distribution of age, gender and inbreeding between the genotype groups (p 
> 0.05). We found no significant differences in the median scores of the cognitive 
tests by rs12344615 genotype (data not shown). We tested the association between 
SNP rs12344615 and the cognitive tests applied and found no statistically signifi-
cant relationship (Table 5).
Discussion
We found no significant difference in risk of AD or PD for carriers of the CC 
genotype of SNP 12344615 in our overall and stratified analyses in the Rotterdam 
Study. We did not detect a significant effect on the onset of AD or PD in this 
population-based sample. In our family based analysis in the GRIP study, we did 
not find a convincing significant association between SNP rs12344615 and AD. 
Marker D9S164 was associated with AD (p = 0.04) and marker D9S185 showed 
borderline association with AD (p = 0.07), however, these associations are nomi-
nally significant and did not sustain when adjusting for multiple testing. Moreover, 
the parametric LOD curve based on 18 microsatellite markers and SNP rs12344615, 
excluded linkage. We detected no effect of this polymorphism on cognitive func-
tion. 
The ubiquilin protein has been shown to interact with presenilin 1 and 2 [5] and 
overexpression of ubiquilin results in a decrease in pen-2 and nicastrin levels. These 
are essential components of the γ-secretase complex, suggesting that ubiquilin 
expression may regulate γ-secretase activity [45]. The UBQLN1 gene is located in a 
region that has been linked to AD (chromosome 9) [4]. In that, the association of 
this gene to AD is plausible. However, studies assessing the relationship between 
the UBQLN1 gene and AD [8-12] have been contradictory. While the studies of 
Silfer [9] and Kamboh [8] found an association between SNP 12344615 and AD, 
age at onset and cognitive function, the studies of Smemo [11] (which analysed 
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seven SNPs including rs12344615), Silfer [10], Browers [12] (which included AD 
cases with onset before 70 years) and more recently the study from Bensemain, 
found no association with AD [13].
Our results do not support a role for UBQLN1 in AD. We studied the relationship 
of SNP rs12344615 both in a large outbred and in an isolated, inbred, populations. 
The Rotterdam Study has a statistical power of 100% to detect a 1.5-2 fold increased 
risk of AD (p = 0.05). The study has a 70% power to detect a similar effect on PD 
assuming an α level of 0.05. Given the lower statistical power for PD studies it is of 
interest that we found a non-significant association to PD. We detected a 1.5-fold 
increase in risk of PD for carriers of the CC genotype of SNP 12344615. This may 
be of interest for further research.
In summary, our results suggest that it is unlikely that the SNP 12344615 of the 
UBQLN1 gene is related to the onset of AD, PD or cognitive function. However, 
our results do not exclude a small effect of the protein on the risk of PD.
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Abstract
The DJ-1 gene is associated with autosomal recessive early-onset parkinsonism, 
most likely through its role in defense against oxidative stress. Oxidative stress 
is not only involved in Parkinson’s disease, but also in other neurodegenerative 
disorders, such as dementia. We assessed the presence of a 14 kb DJ-1 deletion in 
191 patients with dementia, ascertained from the genetically isolated population 
where the first kindred with DJ-1 related parkinsonism was originally identified. 
The control group consisted of 129 non-demented subjects. We found the deletion 
in two patients and one control. There was no evidence for an increased risk of 
dementia in carriers. All subjects were heterozygous for the deletion and related 
to a common ancestor within 8 generations. Our results suggest it is unlikely that 
haploinsufficiency in the DJ-1 gene imparts an increased risk for dementia.
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Introduction
We recently reported mutations in the DJ-1 gene in autosomal recessive early-onset 
parkinsonism [2]. The functional properties of the DJ-1 protein are not fully eluci-
dated. Unlike the three other genes for familial Parkinson’s disease (PD) [9, 11, 18], 
the involvement of DJ-1 in the ubiquitin protein degradation pathway, presently 
considered central in the pathophysiological model for PD [3, 4], is still a matter of 
debate. Previous studies have suggested that DJ-1 plays a role in the cellular defense 
against oxidative stress [16] and Yokota et al. suggested a protective effect of DJ-
1 against proteasome stress, although these results have not been replicated [23]. 
Likewise, in other neurodegenerative conditions, such as Alzheimer’s disease (AD) 
and related disorders, oxidative damage is implicated [7].  Alzheimer’s disease shows 
a considerable overlap with PD pathology. In PD as well as in AD, Lewy bodies 
can be found at postmortem examination [1], while a high number of PD patients 
develop dementia [6, 8]. Inhibition of proteasome function in the pathological state, 
as has been reported in both Alzheimer’s and Parkinson’s disease, could therefore 
contribute both to accumulation of non-ubiquitylated forms of aggregation-prone 
neuronal proteins, as well as impaired clearance of ubiquitylated aggregates [10]. 
There is some evidence of familial aggregation of AD and PD suggesting a com-
mon genetic origin [5]. Li et al showed evidence of a possible overlap of these two 
entities through a role of inflammation in these two neurodegenerative disorders 
[12]. Also Rizzu et al. demonstrated the colocalization of DJ-1 protein within a 
subset of pathological tau inclusions in a diverse group of neurodegenerative dis-
orders known as tauopathies [19]. We hypothesized that mutations in DJ-1 may not 
only concern the strictly defined disease entity AD, but rather a broader range of 
dementias. We assessed the role of DJ-1 mutations in dementia by performing a 
case-control study of dementia patients and controls ascertained from the geneti-
cally isolated population in which the deletion in DJ-1 gene was originally detected 
in a kindred with early-onset parkinsonism [2, 22]. 
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Materials and Methods
Study population
Patients were derived from a study of genetic susceptibility for dementia, performed 
within the framework of the GRIP (Genetic Research in Isolated Populations) study 
[21]. The population in which the study was conducted is a genetically isolated com-
munity in the Southwest of The Netherlands. From a founding population of about 
150 ancestors, this community expanded to a current number of approximately 
20,000 inhabitants. Since there has been little inward migration, a genetically homo-
geneous population arose from the founder population. In this isolate all patients 
with dementia were ascertained through local general practitioners, neurologists 
and nursing-home physicians.
Patient ascertainment
The diagnoses of dementia type (AD, FTD, LBD, and VaD) were made by a research 
physician and two neurologists according to the international NINCDS-ADRDA 
criteria for AD [14], consensus criteria for frontotemporal dementia [17], Lewy 
body dementia [13], and vascular dementia [20]. Genealogical information includ-
ing name, date and place of birth of parents and grandparents was obtained from 
a close relative. These lineages were extended by means of community and church 
registers and a computerized genealogy database. A family-history questionnaire 
was administered in order to ascertain any family history for neurological, vascular 
or psychiatric disease. 
The control group was composed of 129 individuals selected from studies on 
dementia, cardiovascular disease and diabetes mellitus type 2 conducted within 
GRIP. Control individuals with a history of PD, parkinsonism or other neurode-
generative disease were excluded [1]. All patients and controls provided informed 
consent prior to participation. The Medical Ethics Committee of the Erasmus MC 
approved this study.
Statistical and genetic analyses
Presence or absence of the deletion and the clinical diagnosis of dementia were 
coded as dichotomous variables. To examine the association between the DJ-1 dele-
tion and the presence of dementia, Chi-square and Fisher exact tests were performed 
with two-sided significance thresholds of 0.05. Analyses were carried out using 
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SPSS for Windows, V. 11.0. Kinship coefficients between individual carriers of 
the DJ-1 deletion were calculated using the PEDIG software package (http://dga.
jouy.inra.fr/sgqa/diffusions.htm). DNA was isolated from the blood samples using 
standard procedures (salting out method) [15]. All subjects were screened for the 
14-kb deletion extending into the DJ-1 gene, which has been reported in this isolate 
before [2]. In order to establish if the carriers of the deletion were homozygous or 
not, these subjects were genotyped for one of the deleted DJ-1 exons (exon 5 – 354 
bp band). Primers and general PCR conditions are reported elsewhere [2].
Results
In the genetically isolated population, 191 patients with dementia were ascertained 
from 188 independent nuclear families.  The diagnosis of probable AD was estab-
lished in 139 patients (122 with probable late onset and 17 with early onset). Possible 
late-onset AD was diagnosed in 18 patients, and clinically possible early-onset AD 
in four patients. Vascular dementia was clinically diagnosed in 10 patients, Lewy 
body dementia in nine patients, frontotemporal dementia in six patients, and the 
type of dementia was undetermined in five patients.
Through mutation screening we detected the deletion in DJ-1 in two cases, and 
also in one control (Table 1). All three were heterozygous for the deletion. Our data 
shows that there is no evidence for association between the DJ-1 deletion and the 
presence of dementia (OR= 1.35 (95% CI  0.12-15.10, p = 0.80).
Table 1. Mean age and DJ-1 deletion in patients with dementia and controls
* Mean age at onset
    
    
    
    
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Of the two cases who carried of the deletion, one was diagnosed with probable AD, 
and the other with amnestic syndrome. The second one, a man aged 90 years started 
to show signs of forgetfulness at 82 years, with slow deterioration of memory in 
subsequent years. The severity of memory loss showed periodic fluctuations. Twice 
he experienced a transient episode of loss of consciousness. He has no hallucina-
tions and no signs of parkinsonism. According to his family history, his sister had 
dementia.
The other patient, an 86 years old woman, showed a mild and slowly progressive 
AD with onset at 74 years. The disease progressed slowly, with daily fluctuations of 
severity, gradually affecting more areas of cognition. She had no signs of parkin-
sonism or hallucinations. Her family history was negative for dementia.
We found one control to be a DJ-1 deletion carrier. At 67 years, he showed no signs 
of cognitive impairment, dementia or parkinsonism. Apart from diabetes mellitus 
type II, his medical history is negative, and he has no family history of dementia.
By means of genealogical research, 134 patients with dementia of any kind could 
be connected to a common ancestor within 11 generations. The three DJ-1 deletion 
carriers were related within 8 generations, their average kinship coefficient was 
0.0036.Individuals one and three are closely related: the kinship coefficient among 
them is between (1/2) 6 (corresponding to 6 meiosis). Individual number two is 
more distantly related, showing a kinship coefficient with the other carriers that is 
between (1/2) 10 and (1/2) 13 (ten and thirteen meiosis).
Discussion
This case control analysis was designed to assess the association between a deletion 
in the DJ-1 gene and the presence of dementia. Here, we analysed 191 demented 
patients and 129 non-demented controls. We found no association between this 
deletion and the presence of dementia. In this study we found 3 heterozygous car-
riers of the DJ-1 gene deletion (two affected individuals and one control) that were 
related within 8 generations suggestion a common origin of the deletion.
The deletion in the DJ-1 gene was recently associated with autosomal recessive 
early onset parkinsonism in an isolated population in the Netherlands [2] and, even 
though the function of the DJ-1 protein is still unknown, this gene was previously 
described as a possible endogenous indicator of oxidative stress status in vivo [16]. 
The patient series of this study did not include the previously ascertained early 
onset PD patients present in this isolate [2].  At clinical examination, these four 
Chapter 3.4. The DJ-1 gene and dementia
143
patients were cognitively normal but neuropsychological tests were not performed. 
Therefore we cannot exclude the presence of minor neuropsychological abnormali-
ties. Moreover, these individuals are still young to present with dementia [22].
Even though the number of heterozygous carriers in our sample is low and this 
could affect the way we can be able to adequately assess whether there is an as-
sociation with dementia, the present data did not show evidence for an association 
between the DJ-1 deletion and dementia. Most likely, the functional copy of the 
gene present in these carriers supersedes the deleted one. One of the three carrier 
individuals was a cognitively healthy control. Given the age at onset of disease in 
the other two carriers, we cannot exclude that this person is still at risk to develop 
dementia. 
In conclusion, we cannot exclude that carriers of this deletion in the DJ-1 gene have 
a higher risk of developing late onset Alzheimer’s disease. Variations in the DJ-1 
gene different from the deletion we found in this isolate may be associated with 
the risk of dementia. However, our results show that haploinsufficiency in the DJ-1 
gene is not a major risk factor for dementia in this isolated population. 
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Alzheimer’s disease is complex
Alzheimer’s disease (AD) is a heterogeneous disorder and the process of find-
ing genes involved in its pathophysiology is a challenge. Four genes are known 
to be implicated in the onset of AD, the amyloid precursor protein gene (APP) 
[1], presenilin-1 (PSEN-1) [2-6], and presenilin-2 (PSEN-2) [7, 8]. The other gene 
involved in AD pathology is the apolipoprotein (APOE) gene [9-12]. After decades 
of genetic research and hundreds of genes studied in relationship with AD [13], no 
new genes have been consistently associated with the disease.
AD is characterized by Amyloid β (Aβ) aggregation, the main component of 
plaques and, tau hyperphosphorylation and subsequent tangle formation. Further, 
the pathology of AD includes neurovascular dysfunction, cell-cycle abnormalities, 
inflammatory processes, oxidative stress, mitochondrial dysfunction and cholesterol 
metabolism in the brain, among others. The amyloid cascade hypothesis assumes 
that an imbalance between the production and clearance of Aβ in the brain is the 
initiating event ultimately leading to neuronal degeneration and dementia [16]. This 
hypothesis has dominated AD research and subsequent strategies for therapeutic 
drug development for over two decades. Key genetic findings that support this 
hypothesis include: a) mutations in APP, encoding the amyloid precursor protein 
leading to early onset AD b) people with Down’s syndrome, who carry an extra 
copy of the APP gene, develop Aβ plaques and dementia early in life and c) the 
presence of a duplication of the APP locus in families with early onset AD [17] 
results in accumulation of Aβ peptides.
Another key player in AD pathology is the microtubule associated protein tau 
(MAPT). In the brains of AD patients, this protein is hyperphosphorylated, 
truncated and aggregated into neurofibrillary tangles (NFTs). The accumulation of 
abnormally hyperphosphorylated tau is associated with neurofibrillary degeneration 
and dementia. In vitro studies suggest that the tangle formation is partially con-
trolled by the tau protein itself [18]. While various tauopathies have been explained 
by specific mutations in the MAPT gene encoding for tau  [19, 20] the relationship 
between MAPT polymorphisms and AD is still not clear.
Chapter 2.2 describes a linkage and association analysis of 37 Single Nucleotide 
Polymorphism (SNPs) in the region including the MAPT gene, seven other con-
firmed genes and five putative genes in a family based study including 122 AD 
patients from the Genetic Research in Isolated Populations (GRIP) program. GRIP 
is conducted in an isolated population in the southwestern part of the Netherlands. 
In this population, we did not find any evidence of a role of MAPT in AD (chapter 
2.2). We also performed a meta analysis of all studies conducted to date on the 
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MAPT gene and AD stratified by APOE*4 but also this analysis did not yield evi-
dence for a role of MAPT. We did find higher linkage disequilibrium in cases than 
in controls for two SNPs 722 kb upstream of MAPT in the N-myristoyltransferase 
1 (NMT1) gene and also nominally significant association for the haplotypes in 
this region and AD (p=0.02 before multiple testing correction). This result must 
be evaluated further but may be a false positive finding. Finally, our results suggest 
that is unlikely that MAPT is involved in AD.
Another gene, linked recently to tauopathies and of interest to AD is the granulin 
(GRN) gene. This gene was recently associated with tau-negative frontotemporal 
dementia linked to chromosome 17 (FTDP-17) located 1.4 Mb upstream from 
MAPT [21, 22]. Even though its function in the brain is not well understood, patho-
logical studies that followed the identification of this gene suggest that the protein 
encoded by the GRN gene is essential for neuronal survival and even partial loss of 
GRN protein eventually leads to neurodegeneration [55, 56]. It has also been dem-
onstrated that GRN activates mitogen-activated protein kinase (MAPK) signaling 
cascades modulating inflammation processes [26]. In chapter 2.2 we sequenced this 
gene in set of 17 AD patients from the GRIP study that show modest evidence for 
linkage to the region in chromosome 17 where GRN and MAPT are located; we 
did not find any sequence variations in the GRN gene in these patients.
The cyclin-dependant kinase 5 (Cdk5) protein is involved in both the Aβ and tau 
pathways. Evidence is accumulating that Cdk5 is involved in the abnormal phos-
phorylation of tau, contributing to the formation of NFTs [23]. Also, the Cdk5/p35 
complex is a regulator of PSEN-1 metabolism and may be a key protein linking 
NFTs and senile plaques [24]. The evidence for a role of the CDK5 gene in AD is 
scarce and has been studied only in early onset AD. In chapter 2.3 we sequenced the 
CDK5 gene in a family with nine affected individuals and found that the rare allele 
of the SNP rs9278 is present in all affected individuals. This SNP, located 116 bp 
downstream the stop codon, was also over represented in early onset AD patients 
of Dutch and Swedish origin [25]. In chapter 3.1 we studied the association between 
the CDK5 tagging SNPs in the Rotterdam study. This is a population-based study 
of 7983 persons aged 55 or over. The study includes 389 prevalent and 160 incident 
patients with AD. In this population, an association was found between AD and 
another SNP rs2069442, (in single SNP and haplotype analyses) located 269 bp 
upstream the transcription start site. Although the AD GRIP and Rotterdam study 
differ in that the GRIP study is based in an isolated population while the Rotterdam 
Study is based in an outbred population, the finding of association to different 
SNPs in CDK5 is unexpected. Our earlier simulation studies suggest that genetic 
variants with a frequency of 1% or higher are unlikely to disappear from the GRIP 
population [57]. Although the functional effects of these variants is far from clear 
and the association described in chapters 3.1 and 2.3 remains to be confirmed, our 
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studies of this gene suggests that it may be involved in AD.
In this thesis, we studied various other candidate genes, including the gene encod-
ing for the cholesteryl ester transfer protein (CETP). Similar to APOE, CETP is 
involved in the regulation of lipid metabolism. There is some evidence that CETP 
may interact with APOE [58]. In chapter 3.2 we studied the I405V polymorphism 
of CETP gene in relation to AD and investigated whether this polymorphism is 
independently associated with AD, or acts in concert with the APOE gene. We 
found a 1.8-fold increase in AD risk for VV carriers of the I405V polymorphism 
in those without the APOE*4 allele. No association was observed between this 
polymorphism and AD in those with the APOE*4 allele. The difference in the 
relationship between CETP and AD between APOE*4 carriers and non-carriers 
was statistically significant (p for interaction = 0.04). Our results suggest that the 
CETP gene increases the risk of AD independently of the APOE gene, probably 
through the regulation of cholesterol metabolism in the brain.
 
Another candidate gene study performed targeted the ubiquilin1 (UBQLN1) gene 
(chapter 3.3). A recent study suggested that the UBQLN1 gene is the gene explain-
ing the linkage of AD to chromosome 9. SNP rs12344615, located downstream of 
exon 8 on the gene, was associated with AD in a family based sample that showed 
evidence for linkage to chromosome 9 [30]. As this gene is involved in the ubiqui-
tination machinery, it may also play a role in Parkinson’s disease (PD). In chapter 
3.3 we analyzed the association of this SNP with AD, PD and cognitive function. 
We studied this SNP in a large population based study (the Rotterdam Study) and 
the GRIP study [31]. We did not find any significant increase in the risk of AD or 
PD for carriers of the CC genotype of SNP 12344615 in our overall and stratified 
analyses by APOE*4. Further, we did not detect an effect on age at onset of AD or 
PD in. Moreover, we detected no effect of this polymorphism on various cognitive 
tests. In our population there is no evidence for a role of UBQLN1 in AD. Of 
interest for future research is the non-significant association observed between the 
SNP rs1234615 and PD, which may be followed-up further.
The last candidate gene study concerns the DJ-1 gene. Mutations in DJ-1 lead to 
autosomal recessive early-onset parkinsonism, most likely through oxidative stress. 
Oxidative stress is not only involved in PD, but also in dementia. We evaluated 
the relationship between the DJ-1 gene and dementia in chapter 3.4. This case 
control analysis was based in the GRIP population where the first kindred with 
DJ-1 related to PD were originally identified [32]. We found no association between 
the DJ-1 deletion involved in PD and the presence of dementia (OR= 1.35, 95% 
CI 0.12-15.10, p = 0.80). We found 3 heterozygous carriers of the deletion (two 
affected individuals and one control) that were related within 8 generations sugges-
tion a common origin of the deletion. Even though we cannot exclude that carriers 
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of this deletion in the DJ-1 gene have a higher risk of developing late onset AD, 
our results suggest that the PD related deletion in the DJ-1 gene is not a major risk 
factor for dementia in this isolated population.
In this thesis, 2 genome scans are described. The first genome scan was embed-
ded in the isolated population (GRIP). These populations have been shown to be 
a powerful setting for finding genes for both Mendelian and complex disorders. 
One of the most important advantages of the GRIP study population is the avail-
ability of genealogic database of the community.  Currently, the genealogy database 
includes data on over 90,000 people. In chapter 2.1 we performed a genome wide 
screen in the late-onset AD from the GRIP program including 112 AD patients. 
We detected evidence for linkage for previously established loci on chromosomes 
1q23 [33-36] and 10 q23 [34, 35, 38-41]. The genes responsible for linkage are yet 
not known at either locus. In the region of chromosome 1 there are two obvious 
candidate genes for AD, the C-reactive protein (CRP) gene [42] and the nicastrin 
(NCSTN) [43] gene. We sequenced these genes but we did not find any mutation. 
We have now begun with the selection of other candidate genes in this region. 
Further, there was significant evidence for linkage of AD to chromosomes 3q23 
and 18q21. At this stage, we have not resolved whether there are 2 loci or whether 
one of the two regions is a false positive. The linkage of AD to chromosome 3q23 
was accompanied by association to this region, while this was not the case for 
chromosome 18. We therefore focused on sequencing the chromosome 3 region 
first. In this region there are evident candidate genes including the transferrin (TF) 
gene [44], the gene encoding for butyrilcholinesterase (BCHE) [45], the neprilysin 
(MME) gene [46] and the somatostatin (SST) gene. These genes were sequenced 
first but showed no mutations in the coding region or the intron exon boundaries. 
We started sequencing the region between markers D3S1587 (the right border of 
the linked region) and D3S1569 (marker with the highest LOD score). Based on 
the information provided on NCBI’s build 36.1 (http://www.ncbi.nlm.nih.gov/) 
we identified 106 genes (80 confirmed and 26 putative) between these markers. 
A complete overview of the other genes selected for sequencing in this locus is 
shown in Table 1. Up to now we have not been able to find a gene that harbors a 
mutation. In the region on chromosome 18 we did not find any obvious candidate 
gene for mutation screening [13]. According to NCBI’s build 36.1, between markers 
D18S1152 and D18S64 (region with the highest LOD score) there are 16 confirmed 
and five putative genes described which will be used as a starting point for the 
sequencing analysis of this region. 
In chapter 2.3 we present the second genome scan. In a family including 9 AD 
patients, who all carried the APOE*4 allele, there was evidence of 2 regions seg-
regating with the disease on chromosomes 1 and 7. We identified 112 genes in the 
region linked to AD in chromosome 1. We further identified 123 genes between 
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markers D7S661 and D7S2465 in chromosome 7. For chromosome 1, the CASP9, 
TNFRSF1B, and MTHFR genes were identified as the most interesting candidates 
after data mining the literature. The best candidate genes on chromosome 7 were 
CDK5 and NOS3. These genes have been previously associated with AD, [25, 
47-49] or apoptosis [50, 51]. The CDK5 and CASP9 genes were selected first for 
mutation screening. No sequence variations were observed in the coding regions of 
the CASP9 and CDK5 genes but we found that allele A of the SNP rs9278 in the 
3’UTR of the CDK5 gene present in all affected individuals. The CDK5 gene may 
explain the linkage of AD to chromosome 7 in this family; however, we cannot 
exclude epistatic effects of this or other genes on chromosome 7 with a gene on 
chromosome 1 or with APOE.
In this thesis we have performed 5 candidate gene studies and two genome screens. 
Although there is strong evidence for a locus on chromosome 3, the findings of our 
studies are either negative (MAPT, GRN, DJ-1, UBQLN1) or ambiguous (chromo-
some 18, CDK5). These findings reflect those of others working in the field of AD. 
The last decade of AD research has provided a great number of candidate genes 
that have been studied. Despite this enormous effort, many of these results could 
not be replicated. It is important to realize that there have been major limitations 
of the studies conducted to date. Often, the analyses have been based on only one 
SNP, which does not exclude a role of other polymorphisms in the gene. Also the 
studies have been frequently underpowered due to the small number of patients, 
making it difficult to detect genetic variants with only small effects [30]. Finally, a 
major problem encountered in genetic research is that of multiple testing. Since a 
large number of tests are performed in genetic research, the probability that a sig-
nificant association is a false positive is high, in particular if one uses a type 1 error 
of 0.05 for statistical significance [59]. Further, as the a priori probability that a gene 
is involved in a disease is low, even for candidate genes, the posterior probability 
that a significant association is true positive is very low.  These limitations also 
concern our studies, both in GRIP and the Rotterdam study. With the increasing 
number of SNPs available from the high-throughput sequencing efforts that have 
been conducted as part of the HapMap consortium [52, 53] and the increasing 
technological developments, a more detailed characterization of candidate genes 
by multiple SNPs is feasible in large series of patients. An important question is 
how large future studies have to be. Association studies should include at least 550 
cases and 550 controls to detect effects of 1.5-2 explained by variants with allele 
frequencies of 10% or higher. To detect genes with smaller effects may require 
series of thousands of patients if not 10,000. 
An important new development that spun-off from the HapMap project is the 
possibility to conduct genome wide association studies using SNP arrays including 
500,000 to 1,000000 SNPs covering the full genome. The prospects of genome 
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wide association studies aiming to detect genetic variants with small effects, also 
ask for even larger cohorts ranging from 3000 to 10,000 cases. Genome wide as-
sociation analysis will allow the identification of new genes and detailed evaluation 
of candidate genes. The major limitation at present is the costs related with the 
genotyping assays, but prices are expected to go down. Also there are a number of 
methodological problems to be tackled, in particular when targeting common vari-
ants associated with a small increase in risk. For these variants, it will be very dif-
ficult to distinguish those from the large number of false positive associations that 
are inevitability to occur in genome wide analysis of large series [60]. Replication 
studies may be a way to distinguish the true and false positive findings. This asks 
for multicenter collaborative studies. A key issue will be to standardize studies a 
priori to allow for replications.
Another important development in technology concerns the production of a 
technology capable of sequencing the human genome in a fast, cheap and reliable 
way. The new sequencing technologies are based on different approaches including 
parallel bead arrays, capillary electrophoresis and biochips among others. These 
will allow sequencing of up to 90 Mb with high quality results (accuracy higher 
than 99.99%) but at a high price. Next generation sequencers offer promising 
prospects of being able to screen up to 1 Gb of DNA but still these methodologies 
are not precise enough which limits the use of this technology in available popula-
tions. These developments are particular useful in the identification of genes, in 
regions identified in linkage studies. So far, several AD loci have been localized 
(chromosomes 1, 9, 10 and, 12) but it has been difficult to identify the causal genes 
in this region. High-throughput sequencing technologies are a very important tool 
to resolve this problem in the future. 
Finally, the implementation of systems biology in research will be important in 
future research. Systems biology seeks to integrate different levels of information 
to understand how biological systems function by the study of the relationships 
and interactions between its various parts. It offers the potential to understand the 
complexity of human brain aging and neurodegenerative diseases. Systems biology 
based bioinformatic tools will help not only in the selection of suitable candidate 
genes or rather candidate gene pathways that can be studied simultaneously but also 
allows to evaluate and rank candidate genes in regions linked or associated to AD. 
Systems biology may form a biological basis for studies of interactions of genes. 
A major problem in complex traits such as AD is that many interactions between 
genes and environmental risk factors may occur. Although statistical interactions 
are found, these have been extremely difficult to replicate. Systems biology may 
provide a valuable tool in the future for the evaluation of the biological plausibility 
of these interactions.
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Summary
Alzheimer’s disease (AD) is the most frequent cause of dementia and thus is a major 
public-health problem. Age and genetic predisposition to the disease are the most 
important risk factors. In 2001 more than 24 million people in the western world 
had dementia. This number is expected to double every 20 years up to 81 million 
in 2040 because of the anticipated increase in life expectancy. Genetically, AD is a 
heterogeneous disorder with both familial and sporadic forms.
Chapter 1 is a general introduction on epidemiological and genetic factors of AD 
and also describes the different studies performed in this thesis.
In chapter 2 the linkage studies are presented. Chapter 2.1 describes a whole ge-
nome screen on 112 AD patients and their first-degree relatives from the Genetics 
Research in Isolated Populations (GRIP) study. Of the 112 patients, 103 could be 
connected into an extremely large and complex pedigree. This pedigree cannot be 
analyzed with available linkage software. In this study, we developed an algorithm 
for splitting complex pedigrees to allow us to conduct linkage analysis. Then we 
determined genome wide significance thresholds for linkage analysis using the sub 
pedigrees obtained by our pedigree cutting algorithm and finally, we performed 
linkage analysis sing these sub pedigrees. We localized 3 loci previously described 
to be involved in AD on chromosomes 1, and 10 yielding a strong proof of principle 
of our splitting method. We also identified genome wide significant novel loci for 
AD on chromosomes 3q23 and 18q21, since the same family contributes to both 
loci we must stablish if our findings represent false positives. We sequenced the ob-
vious candidate genes on chromosome 1, nicastrin (NCST) and C-reactive protein 
(CRP) but no mutations on these genes were found. Since we found evidence for 
association with AD to the locus on chromosome 3, we also sequenced 21 genes 
on this locus including the transferrin gene, the gene encoding for butyrilcholines-
terase, the neprilysin gene and the somatostatin gene. We screened these genes for 
mutations but nohave been found. 
In chapter 2.2 we present a combined linkage and association study between the 
microtubule associated tau protein (MAPT) and granulin (GRN) genes and AD. 
In this study we investigated the association between the region including MAPT 
plus other eight confirmed genes (including the GRN gene) and five putative genes 
and AD in patients from the GRIP study. We studied 122 AD patients and 85 
control subjects using an extensive Single Nucleotide Polymorphism (SNP) panel. 
No association was found for any individual SNP of the MAPT gene and linkage 
analysis including 7 tagging SNPs in MAPT excluded linkage. Nominally signifi-
cant association was found for two SNPs located 722 kb upstream the MAPT gene 
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in the N-myristoyltransferase 1 (NMT1) gene. The GRN gene was sequenced in 
17 patients but no mutations were found. We also performed a meta analysis of 
all studies conducted to date on the associations between the MAPT gene and 
AD stratified by APOE*4. We found a very modest non-significant association for 
carriers of the H2 haplotype compared to H1/H1 carriers, only in those with the 
APOE*4 allele. These findings suggest that the MAPT and GRN genes do not play 
a role in AD in our population.
In AD, in chapter 2.3 we performed a genome wide linkage analysis on an extended 
Dutch family with nine affected individuals. Two linkage peaks above 1.0 were 
found on chromosomes 1 and 7. A further two locus linkage analyses using only 
affected individuals yielded a LOD score of 2.92 for the combination of these 2 loci 
suggesting an epistatic effect between these two loci. We used a literature mining 
strategy to prioritize candidate gene selection from the genes present in the defined 
loci. Our literature mining approach suggested as potential candidate genes in these 
two regions the CASP9, TNFRSF1B and MTHFR genes on chromosome 1 and 
CDK5 and NOS3 on chromosome 7. These genes have been previously associated 
with AD and apoptosis. CASP9 on chromosome 1 and CDK5 on chromosome 
7 were selected for sequencing. We found no variants in the coding exons or the 
splice sites of these genes but we found the rare allele of SNP rs9872 on the CDK5 
gene present in all affected individuals suggesting that this gene maybe involved in 
AD in this family.
Chapter 3 describes the genetic association studies performed in this thesis. Three 
studies were carried out using the Rotterdam Study (chapters 3.1-3.3) a large 
prospective study of determinants of diseases in the elderly and one in the GRIP 
study (chapter 3.4). In chapter 3.1 we tested the association between 5 SNPs on the 
CDK5 gene and AD. We found a significantly increased risk of AD for carriers 
of the GG genotype of SNP rs2069442 (OR=1.8, 95% CI 1.16-2.79, p=0.009) in 
those without APOE*4.. Our haplotype analysis showed that haplotype C, tagging 
the G allele of SNP rs2069442, was significantly associated (p=0.05) to AD. These 
result suggest that alterations in the expression of the Cdk5 protein may be relevant 
in neurodegenerative processes Taken together, the results of chapters 2.3 and 3.1 
underscore the relevance of this gene on AD.
We also evaluated the relationship between the cholesteryl ester transfer protein 
(CETP) and AD in chapter 3.2. Here we show that there is a positive associa-
tion between the VV carriers of the I405V polymorphism of the CETP and AD 
independently of the APOE gene and systemic HDL levels. Since the VV genotype 
is associated with lower levels of CETP and higher HDL, our study is compatible 
with the view that low CETP levels may increase the risk of AD through a reduc-
tion in neuronal repair capacity.
Summary
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In chapter 3.3 we investigated the relationship between the ubiquilin 1 (UBQLN1) 
gene and AD, Parkinson’s disease (PD) and cognitive function. This gene is in-
volved in the ubiquitination machinery, related with general protein degradation. 
A SNP located downstream of exon 8 (rs12344615) of the UBQLN1 gene has been 
associated with AD. We found no significant difference in risk of AD or PD for 
carriers of the CC genotype of SNP 12344615 in our overall and stratified analyses 
in the Rotterdam Study. We did not find an association of this SNP and AD in 
our family based study, we did not find linkage of AD to the region including the 
UBQLN1 gene, and we detected no effect of this polymorphism on cognitive func-
tion. Our data suggest that it is unlikely that the SNP 12344615 of the UBQLN1 
gene is related to AD, PD or cognitive function.
Chapter 3.4 shows the relationship between a 14-kb deletion extending into the 
DJ-1 gene and dementia using a case-control study of dementia patients and con-
trols ascertained from GRIP study. We analysed 191 demented patients and 129 
non-demented controls. We found no association between this deletion and the 
presence of dementia. There were 3 heterozygous carriers of the DJ-1 gene deletion 
(two affected individuals and one control) that were related within 8 generations 
suggestion a common origin of the deletion. Form our results we cannot exclude 
that carriers of this deletion in the DJ-1 gene have a higher risk of developing AD. 
Variations in the DJ-1 gene different from the deletion may be associated with the 
risk of dementia. However, our results show that haploinsufficiency in the DJ-1 
gene is not a major risk factor for dementia in this isolated population.
Finally, chapter 4 provides a general discussion on the results obtained on the stud-
ies on AD presented in this thesis and all findings are put into perspective for 
future studies.
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Samenvatting
De ziekte van Alzheimer (AD) is de meest voorkomende oorzaak van dementie 
en daarmee een belangrijk public health probleem. De belangrijkste risicofacto-
ren voor AD zijn leeftijd en genetische aanleg. In 2001 leden in Westerse landen 
meer dan 24 miljoen mensen aan dementie. Door de voorspelde toenames in de 
levensverwachting (vergrijzing) zal naar verwachting zal dit aantal elke 20 jaar ver-
dubbelen en toenemen tot 81 miljoen patiënten in het jaar 2040. Vanuit genetisch 
oogpunt bezien is AD een heterogene ziekte, met zowel familiaire als sporadische 
varianten.
Hoofdstuk 1 is een algemene inleiding waarin achtergrondinformatie over epide-
miologische en genetische invloeden op AD wordt gegeven. Ook worden in dit 
hoofdstuk de verschillende studies die aan dit proefschrift ten grondslag liggen be-
schreven. In hoofdstuk 2 worden de resultaten van koppelings analyses beschreven. 
We voerden een koppelings analyse uit op de volledige genomische data van een 
groep van 112 AD patiënten en hun eerstegraads familieleden die deelnamen aan 
de Genetics Research in Isolated Populations (GRIP) studie; de resultaten hiervan 
staan beschreven in hoofdstuk 2.1. Van de 112 patiënten konden er 103 teruggeleid 
worden naar een zeer grote en complexe stamboom, die niet met de beschikbare 
linkage programmatuur geanalyseerd kon worden. Daarom ontwikkelden we een 
algoritme waarmee complexe stambomen opgesplitst kunnen worden. Gebruik 
makend van deze sub-stambomen werden voor de volledige genomische data 
significantie-drempelwaarden bepaald voor koppelings analyse, waarna we de link-
age-analyses konden uitvoeren. 
We lokaliseerden 3 loci op de chromosomen 1, 3 en 10, waarvan al eerder een 
verband met AD beschreven was. Dit gaf sterke aanwijzingen dat ons algoritme 
in principe werkte. We ontdekten ook een nieuw locus voor AD op chromo-
soom 18q21. Bij  sequencing van de voor de hand liggende kandidaat-genen op 
chromosoom 1, nicastrin (NCST) en C-reactive protein (CRP) vonden we geen 
mutaties binnen deze genen. Op het locus op chromosoom 3 doorzochten we de 
hele (exonische en splice donor sites) DNA volgorde van 21 genen, waaronder het 
transferrine gen, het gen dat codeert voor butyrilcholinesterase, het neprilysine gen 
en het somatostatin gen. Bij het screenen van deze genen op mutaties werden geen 
varianten gevonden.
In hoofdstuk 2.2 wordt een gecombineerde koppelings- en associatie studie tussen 
de microtubule-geassocieerde tau proteïne (MAPT) en granuline (GRN) genen en 
AD beschreven. Voor deze studie onderzochten we de associatie tussen de regio 
waarop MAPT en acht andere bevestigde genen (waaronder het GRN gen) liggen 
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en vijf mogelijke genen en AD bij patiënten uit de GRIP studie. We onderzochten 
gegevens van 122 AD patiënten en 85 controle-personen, gebruik makend van 
een uitgebreid Single Nucleotide Polymorphism (SNP) panel. Voor geen enkele 
SNP van het MAPT gen werd een associatie gevonden. Koppelings analyse van 
7 tagging SNPs in MAPT maakte duidelijk dat er geen sprake van koppeling was. 
Een nominaal significante associatie werd gevonden voor twee SNPs die 722 kb 
upstream liggen van het MAPT gen binnen het N-myristoyltransferase 1 (NMT1) 
gen. Het GRN gen werd bij 17 patiënten gesequenced maar er werden geen muta-
ties gevonden. We voerden een meta-analyse uit van alle studies die tot dan toe 
waren uitgevoerd met betrekking tot de associatie tussen het MAPT gen en AD, 
gestratificeerd voor APOE*4. Er werd een heel klein, niet-significant verband 
gevonden voor dragers van het H2 haplotype in vergelijking met de  H1/H1 drag-
ers, uitsluitend bij diegenen met het APOE*4 allel. Deze resultaten suggereren dat 
de MAPT en GRN genen geen rol spelen bij AD binnen onze populatie. 
Het doel van het onderzoek dat ik hoofdstuk 2.3 beschreven is was om genen te 
ontdekken die betrokken zijn bij AD. We voerden een koppelings analyse uit op de 
volledige genomische data binnen een uitgebreide Nederlandse familie, waarvan 9 
personen AD hadden. Er werden twee koppelingspieken groter dan 1.0 gevonden 
op chromosomen 1 en 7. Vervolgens werden in twee koppelings analyses waarbij 
alleen de gegevens van aangedane personen werden geanalyseerd resulteerde in een 
LOD score van 2.92 voor de combinatie van deze 2 loci, wat een epistatisch effect 
tussen deze loci suggereert. Een literatuur mining strategie om prioriteiten te kun-
nen stellen tussen de potentiele kandidaat genen die op de gedefinieerde loci liggen. 
Deze benadering suggereerde dat de potentiele kandidaatgenen in de regio op chro-
mosoom 1 de genen CASP9, TNFRSF1B and MTHFR waren. Voor chromosoom 
7 waren dit de genen CDK5 en NOS3. Van deze genen zijn al eerder associaties met 
AD en apoptose beschreven. We selecteerden CASP9 op chromosoom 1 en CDK5 
op chromosoom 7 om te sequencen. Er werden geen varianten in de coderende 
exonen of de splice sites van deze genen, maar we ontdekten dat het zeldzame allel 
van SNP rs9872 van het CDK5 gen aanwezig was bij alle aangedane personen, wat 
erop wijst dat dit gen betrokken zou kunnen zijn bij AD in deze familie.
Hoofdstuk 3 beschrijft de genetische associatie studies die binnen het kader van dit 
proefschrift werden uitgevoerd. Er werden drie studies uitgevoerd (hoofdstuk 3.1-
3.3) binnen het cohort van de Rotterdam Studie; een groot prospectief onderzoek 
dat is opgezet om ziekten bij ouderen te bestuderen. Ook werd een onderzoek 
uitgevoerd binnen de GRIP (Genetic Research in Isolated Populations) studie 
(hoofdstuk 3.4). In hoofdstuk 3.1 testten we of er een associatie was tussen 5 SNPs 
op het CDK5 gen en AD. Binnen de groep mensen zonder APOE*4 bleken dragers 
van het GG genotype van SNP rs2069442  een significant verhoogd risico voor AD 
te hebben (OR=1.8, 95% BHI 1.16-2.79, p=0.009). De haplotype analyse demon-
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streerde dat haplotype C, die het G allel van SNP rs2069442 markeert, significant 
geassocieerd was met AD (p=0.05). Deze resultaten suggereren dat veranderingen 
in de expressie van het CDK5 eiwit relevant zou kunnen zijn voor neurodegenera-
tieve processen. De resultaten van hoofdstuk 2.3 en 3.1 illustreren hoe belangrijk 
dit gen is voor AD. 
In hoofdstuk 3.2 evalueerden we het verband tussen het cholesteryl ester transfer 
proteïne (CETP) en AD. Er werd een positief verband gevonden tussen de VV 
dragers van het I405V polymorfisme van het CETP en AD dat onafhankelijk was 
van het APOE gen en systemische HDL niveaus. Aangezien het VV genotype 
geassocieerd is met lagere CETP en hogere HDL spiegels, passen deze bevindingen 
binnen de theorie dat lage CETP spiegels de kans op het krijgen van AD kunnen 
verhogen door middel van een reductie in de neurale repair capaciteit.
In hoofdstuk 3.3 onderzochten we het verband tussen het ubiquiline 1 (UBQLN1) 
gen en AD, de ziekte van Parkinson (PD) en cognitieve functie. Dit gen speelt een 
rol in de ubiquitinatie macherinerie en is gerelateerd aan algemene eiwit degradatie. 
Een SNP die downstream van exon 8 (rs12344615) op het UBQLN1 gen ligt, was 
al eerder geassocieerd met AD. We vonden geen significant verschil in de kans op 
het krijgen van AD of PD voor dragers van het CC genotype van SNP 12344615 
in onze algemene en gestratificeerde analyses binnen de Rotterdam Studie. Er 
werd geen verband gevonden tussen deze SNP en AD in onze family based studie, 
vonden geen linkage van AD met de regio waarin het UBQLN1 gen ligt, en vonden 
geen effect van dit polymorfisme op cognitieve functie. Uit onze gegevens blijkt dat 
SNP 12344615 van het UBQLN1 gen waarschijnlijk niet gerelateerd is aan AD, PD 
of cognitieve functie.
Hoofdstuk 3.4 beschrijft de relatie tussen een 14-kb deletie die reikt tot binnen het 
DJ-1 gen en dementie, zoals die gevonden werd in een patiënt-controle studie van 
dementie patiënten en controlepersonen uit de GRIP studie. We analyseerden de 
gegevens van 191 patiënten met dementie en 129 controlepersonen die niet leden 
aan dementie. Er werd geen verband gevonden tussen deze deletie en dementie. Er 
waren 3 heterozygote dragers van de DJ-1 gen deletie (twee aangedane patiënten en 
één controlepersoon) die binnen 8 generaties gerelateerd waren, wat een gemeen-
schappelijke oorsprong van de deletie suggereert. Gebaseerd op deze resultaten 
kunnen we niet uitsluiten dat dragers van deze deletie in het DJ-1 gen een ver-
hoogde kans hebben om AD te krijgen. Variaties binnen het DJ-1 gen, anders dan 
de deletie, kunnen geassocieerd zijn met het risico op dementie. Onze resultaten 
tonen wel dat haploinsufficientie in het DJ-1 gen geen belangrijke risicofactor voor 
dementie is binnen deze geïsoleerde populatie. 
In het laatste hoofdstuk, hoofdstuk 4, worden de resultaten van deze studies 
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naar AD bediscussieerd. Ook worden alle bevinden in perspectief geplaatst voor 
toekomstige studies. 
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